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THE INFLUENCE OF DEMOGRAPHIC, SOCIAL, AND ECONOMIC FACTORS ON
REFERRAL FOR HEART FAILURE SERVICES

Catherine Elaine Kelty, Ph.D.
Western Michigan University, 2022

Patients with end-stage advanced heart failure must go through an extensive evaluation
process before being selected for either heart transplantation or left ventricular assist device
(LVAD). This evaluation not only assesses a patient’s medical need for advanced heart failure
treatments but also includes an assessment of psychosocial and economic factors that may affect
a patient’s success post-treatment. While it is important to allocate scarce resources, such as
donated organs, to the patients who will benefit the most, there is also a need for equity in the
allocation of and access to healthcare services. This raises the question of whether patients who
are diagnosed with heart failure ever have the opportunity to be evaluated for advanced heart
failure services in the first place, due to gatekeeping events that may prevent patients from being
referred to or have an appointment with a specialist.
The independent variables age, sex, marital status race/ethnicity, preferred language,
smoking status, and insurance status were compared between patients referred and not referred,
who had a clinic visit and did not have a clinic visit, and who received treatment and did not
receive treatment. Patients who were younger (HR 0.934, 95% CI 0.925, 0.943), males (HR
2.216, 95% CI 1.544, 3.181), married (HR 0.665, 95% CI 0.488, 0.905), or non-smokers (HR
0.549, 95% CI 0.389, 0.776) were more likely to be referred to a specialist. Married patients
(p=0.024) and nonsmokers (p=0.039) were more likely to have a clinic visit and younger age was

shown to contribute as well (HR 0.981, 95% CI 0.966, 0.995). Younger age (B coefficient = 0.21; HR 0.980 [95% CI 0.961, 0.998]), White race (p=0.042), Hispanic/Latino ethnicity (B
coefficient = 1.504; HR 4.501 [95% CI 1.574, 12.875]), and both public (B coefficient = -0.758;
HR 0.468 [95% CI 0.270, 0.813]) and private insurance (p=0.027) were significantly influencing
whether patients received a heart transplant. Hispanic ethnicity was also associated with
receiving an LVAD (HR 33.833, 95% CI 3.207, 356.968). Advanced age, Hispanic ethnicity,
and smoking were associated with one-year mortality after heart failure diagnosis.
This study confirmed that disparities in access exist before patients are ever evaluated for
advanced heart failure therapies. The gatekeeping events preventing patients from referral are
multifactorial and based on historical injustices and structural barriers outside of the scope of
healthcare. Recommendations for improving equity in access include improved heart failure
guidelines for referral, cultural bias training for healthcare professionals, and government-led
initiatives to provide universal financing for transplantation.
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CHAPTER I
INTRODUCTION
Significance of the Research
Despite medical advances, there is no cure for AHF (AHF). Patients with AHF are in
such an advanced disease state that they cannot be managed by conventional medical treatments
such as medication or surgery. For these patients, cardiac transplantation is the best available
intervention. The next best treatment is the left ventricular assist device (LVAD), which is a
surgically implantable, mechanical pump that provides circulatory support, either while the
patient waits for a transplant or long-term support if the patient is ineligible for transplant. 1 Heart
transplantation provides the best outcomes, with 91% one-year survival and LVAD providing
82% one-year survival.2 Candidates for both cardiac transplantation and LVAD must undergo an
extensive selection process before becoming eligible for either treatment. Organs are a scare
resource with inherent restrictions on their availability and access. Both transplantation and
LVAD implantation require extensive lifelong medical management, making patient selection a
crucial step toward determining appropriate candidacy.
There are national policies to dictate the allocation practices of donor organs, but
transplant programs are responsible for selecting patients that are in medical need and are likely
to have a successful transplant. The autonomy of each transplant program allows for variability
in how patients are selected to be candidates for transplantation, and it is not until they are
candidates that the national policies are applicable. The United Network for Organ Sharing
(UNOS) and the Organ Procurement and Transplantation Network (OPTN) are responsible for
developing the policies for organ procurement and allocation in the United States. UNOS is a
1

private, non-profit organization based in Richmond, Virginia that is under contract with the
United States Department of Health and Human Services (DHHS). UNOS serves as the OPTN
and manages all organ transplantations in the United States.
An allocation system is necessary due to the scarcity of donor organs. Factors such as
distance from the donor hospital, blood type, and the medical need of the candidate play a role in
how donor hearts are allocated.3 The National Organ Transplant Act (NOTA), a federal law
passed in 1984, requires that the allocation system for donor organs must account for both
efficiency and equity.4 Equity is important so that there is justice in allocation, and efficiency
allows for increased survival and number of recipients. 3 However, there are no regulations
insisting on equitable allocation as part of the selection process at the transplant hospital.
Eligibility for AHF treatments such as transplant and LVAD involve an extensive
selection process. Organizations under contract with the U.S. government such as the United
Network of Organ Sharing (UNOS) or the Organ Procurement and Transplantation Network
(OPTN) have no regulations or requirements for the institutional selection procedures, and it is
up to each transplant program to develop their own guidelines. Therefore, even though the
allocation system put in place by UNOS and OPTN is uniform and considers justice and medical
utility, each transplant center develops their own criteria for candidacy of both transplantation
and LVAD implantation.
The International Society of Heart and Lung Transplantation (ISHLT), Academy of
Psychosomatic Medicine, American Society of Transplantation, International Consortium of
Circulatory Assist Clinicians, and the Society for Transplant Social Workers collaborated to
produce a guidance document for individual transplant programs which outlines
recommendations for the psychosocial assessment of transplant or LVAD candidate. 5 This
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included guidance for such factors as social support, cognitive impairment, substance use, and
substance abuse. Notably, OPTN policies state that allocation should not be dependent on
financial status,6 but eligibility based on ability to pay is left to the individual transplant
programs to determine. The financial evaluation is in fact a part of the evaluation process for
transplant and LVAD at transplant programs across the country. According to a national survey,
48% of heart transplant programs require proof of appropriate insurance coverage before
evaluation for transplant and 84% require coverage before listing. 7 Recent research has shown
that patients with Medicare or Medicaid were less likely to be eligible for a transplant when
compared to privately insured patients.8
This leads to the question if there are gatekeeping events keeping patients from seeing an
AHF specialist in the first place, despite clinical eligibility. There is currently a deficit in the
literature investigating referrals to heart failure services, and the research that does exist is
focused on the clinical aspects of referral.9,10 Understanding physician decision-making during
the clinical evaluation is difficult, as decisions are based on clinical, social, and personal
characteristics.11 The inherent restrictions witnessed in the evaluation process for advanced
therapies therefore lead us to investigate whether there are disparities in access to services before
a patient receives an advanced therapy evaluation, and whether the disparities are caused by
social or economic factors.
This study builds on previous, unpublished12 research by the author, which investigated
the demographic, psychosocial, and socioeconomic factors affecting eligibility for AHF
interventions such as heart transplant and LVAD and whether these treatments were received.
That research found that public insurance and social support were significant factors in the
selection process. The proposed study takes a step back, asking whether or not the access to heart
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failure treatments exists only at the level of advanced therapies or if patients are determined to be
unsuitable earlier in their disease trajectory.
This study provides evidence regarding potential issues with access and eligibility for
AHF services because the patients not referred for heart failure services have not been
investigated before. Limited research has been done on referrals because the data related to
physician-decision making is not readily available and required detailed chart review. 11 This
research assesses whether there are points of access before the patient has a chance to go through
the transplant and LVAD evaluation process. The study was conducted at one Midwest hospital
system with a transplant program that serves 13 counties. 13 Even a single center study such as
this may have far-reaching implications, as patients and providers strike for justice in access to
healthcare services. Ultimately, this research has the potential to produce practice changes that
may reduce disparities in referral.

Statement of Purpose
The aim of this research was to understand the extent to which disparities in referral
influence utilization of AHF services. To do this, the progression of heart failure care at one
Midwest hospital system with a transplant and LVAD program was examined. The study
identified demographic, social and economic factors that differed between patients referred for
and able to receive AHF services, and those that were not referred or did not receive services.
Patients with social determinants of health are hypothesized to be less likely to be referred for
and receive AHF services. Findings from this research may provide information to increase use
of AHF therapies in vulnerable populations.

4

Research Questions
The following questions will be asked:
1.) Do patients who were diagnosed with heart failure and referred for AHF services
differ from patients diagnosed with heart failure and were not referred with regards to
demographic, social, and economic factors?
2.) Do patients who were referred for AHF services and had a clinic visit with an AHF
specialist differ from patients referred but did not have a clinic visit with regards to
demographic, social, and economic factors?
3.) Do patients who had a clinic visit and received AHF treatment (transplant and
LVAD) differ from patients who had a clinic visit and did not receive AHF
treatment?
4.) Does the length of time from diagnosis to referral, diagnosis to clinic visit, diagnosis
to treatment, and/or diagnosis to death differ based on demographic, social, and
economic variables?

Definition of Terms
1. Advanced heart failure (AHF): An advanced subset of heart failure with severe,
persistent symptoms despite medical management. 14
2. Advanced therapy: A heart transplant or mechanical circulatory support, such as an
LVAD, for treatment of heart failure.15
3. Heart failure: A complex clinical syndrome resulting in impaired ventricular filling or
ejection of blood.14

5

4. Heart transplant: The surgical removal of a diseased heart and replacement with a
healthy heart from a deceased donor in an effort to increase lifespan and improve quality
of life.16
5. Left ventricular assist device (LVAD): A type of mechanical circulatory support used to
treat patients with AHF, consisting of a mechanical pump that provides circulatory
support.1

Chapter Summary
Patients with AHF are in an advanced disease state with limited medical options, and a
heart transplantation or LVAD are the best available treatment option. There is an extensive
evaluation process for the selection of heart transplant and LVAD candidates due to the scarcity
of donor organs and lifelong medical management required for either therapy. It is unknown
what barriers exist that prevent patients with heart failure from undergoing an evaluation with an
AHF specialist. Whether demographic, social, and economic factors affect referral to the AHF
clinic and patient visits with an AHF specialist in one Midwest hospital system will be
investigated.

6

CHAPTER II
REVIEW OF LITERATURE
Due to the selection process for AHF services, lifesaving treatments will not be provided
to everyone in medical need. While selection of the most appropriate candidates for services is
imperative for success, a patient’s demographic, social, and economic characteristics play a role
in eligibility resulting in inequitable distribution of services. This section examines the trajectory
from heart failure diagnosis through the referral process and ultimately eligibility for advanced
services. Understanding the criteria that prevent patients from receiving AHF services after a
referral is essential in investigating whether these same barriers exist before a patient receives a
referral for AHF services.
Heart Failure
The American College of Cardiology Foundation and the American Heart Association
define heart failure as “a complex clinical syndrome that results from any structural or functional
impairment of ventricular filling or ejection of blood.”14 Heart failure often involves pericardium,
myocardium, endocardium, or great vessels disorders, but most patients have impaired left
ventricular myocardial function.17 As of 2019, an estimated 6.2 million Americans over the age
of 20 years old had heart failure.18 Risk factors for heart failure include hypertension, diabetes
mellitus, metabolic syndrome, and atherosclerotic disease. 14
Some patients with heart failure are in such an advanced disease state that they cannot be
managed by medication or standard surgery. For those patients, the best available treatment is a
heart transplantation, with the next best option being an LVAD. Both treatments require lifelong
medical management. A heart transplant is the surgical removal of the diseased heart and
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replacement with a healthy heart from a deceased donor.16 A heart transplant recipient must take
immunosuppressants for the rest of their life so that their body does not reject the new heart. An
LVAD is a surgically implanted device that supports heart function and the flow of blood out of
the heart.1 The LVAD consists of the pump placed inside the body, tubes that carry blood from
the heart to blood vessels, a power source for the pump, and an electronic controller for the
pump. The pump is connected to the external controller by a driveline that passes through the
skin from the inside to the outside of the patient’s body. 1 The device must be connected to a
power source at all times, therefore the patient must either carry a battery pack or plug the device
directly into a wall outlet. Daily dressing changes at the driveline exit site in the abdomen are
required to reduce the risk of infection and may require the assistance of a caretaker. Many
LVAD recipients take anticlotting medications due to the increased risk for blood clots when
blood is in contact with the device.1
LVADs may be utilized as bridge-to-transplant (BTT), meaning the patient is implanted
with an LVAD while they wait for a donor heart to become available. As more patients have
been stabilized and supported by LVADs as BTT, the number of heart transplant candidates has
increased as well.19 LVADs may also be used as destination therapy (DT), in which an LVAD is
used in heart failure patients that may be ineligible for a heart transplant. Further, some heart
transplant candidates may not be eligible to be supported by an LVAD due to their specific
anatomy or nature of their heart failure.

Referral for Advanced Heart Failure Services
In recent years, the gatekeeping model has become more prominent in the United States
health care system.20 In this model, a primary care practitioner must refer a patient before they
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may have an appointment with a specialist. This system is meant to avoid unnecessary, costly,
and invasive procedures21 in addition to providing preventive, routine care and total coordination
of an individual’s health care needs.20 However, some insurance policies, such as a preferred
provider organization (PPO) plan, may allow patients to go directly to a cardiologist without a
referral.11
For patients with heart failure, they are often first seen by their primary care physician,
and it is there that they may be first diagnosed with heart failure. Many patients with heart failure
present to their healthcare provider with decreased exercise tolerance, symptoms of fluid
retention, or the patient may have no cardiac symptoms and cardiac dysfunction may be noticed
as an incidental finding.17 The physician must assess disease severity and request appropriate
testing. Based on those results, the patient may then receive a referral to a cardiologist and
potentially a second referral to a heart failure cardiologist. Referral to the heart failure clinic is
indicated based on clinical deterioration despite optimal care, including medications such as
angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, aldosterone
antagonist, hydralazine, and/or isosorbide dinitrate, or an implantable cardioverter defibrillator or
resynchronization therapy.9 Markers for referral include the commonly used New York Heart
Association functional classifications of III or IV, intolerance to heart failure medication,
hypotension, anemia, decreased renal function, and/or recurrent heart failure hospitalizations. 10
At the heart failure clinic, the patient may finally receive an evaluation by a surgeon specializing
in heart transplant or LVAD services.22
When a patient meets the criteria for an evaluation with an AHF specialist, it is up to the
primary care physician or cardiologist to make that referral. Even if the patient has a known
contraindications to AHF therapies, such as active malignant disease or noncompliance, the
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patient should still be referred to see a heart failure specialist who will conduct their own
evaluation.9 Ideally, the patient is medically stable as the time of the long, complex evaluation
process but, at times, this evaluation is conducted in an urgent and accelerated manner. A
patient-specific risk-benefit analysis should be performed and include patient preferences,
center-specific protocols, and consideration for post-transplant or post-LVAD outcomes. 9
While bias may be introduced at any step in the specialist referral process, a specific area
of concern is when patients may not be referred at all and why that situation may occur. Current
research has focused on the heart failure specialist while limited research has been done on the
patient’s initial presentation to their primary care physician with heart failure symptoms. The
main reason patients are not referred to heart failure specialists is likely due to insufficient
understanding of the disease by primary care clinicians and lack of clear guidelines to identify
appropriate patients.23 The primary care physician and/or cardiologist must believe that certain
tests or procedures are warranted for patient evaluation. Referral or non-referral may be based on
something as simple as the relationship that exists between the referring physician and the
specialist,11,24 and concerns have been made that clinician bias could negatively affect the
patient-clinician relationship.25

Clinician Decision-Making
The primary care physician or cardiologist has an important role in the clinical care a
patient with heart failure may receive. While it is expected that clinical decision-making is based
on evidence-based practices, a number of non-clinical factors may influence clinical decisions. 24
Referral bias is the non-referral of certain populations, i.e., the uninsured, for evaluation by a
specialist, or a hospital or institution not accepting certain populations of patients.26 The term
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bias may be defined as the negative evaluation of the members of one group compared to
another.27 In most cases, bias in healthcare is implicit, meaning the clinician is unconsciously and
unintentionally biased against members of a particular social group. Just as biases exist in all
areas of society, implicit bias may influence clinical decision-making and ultimately promote
disparities in health care.27
According to the Institute of Medicine, three factors caused by providers might be
involved in promoting healthcare disparities based on race/ethnicity: bias or prejudice against
minorities, increased clinician uncertainty during interactions with minority patients, and
provider-held stereotypes about the health or behavior of minorities. 25 Research suggests that
physician bias can impact decision-making and promote health care disparities. Quantitative24
and qualitative28 research has demonstrated that clinical decisions are not only made by medical
information and that patient race/ethnicity play a factor. When black and white patients present
to the emergency room with similar levels of pain, black patients are less likely to receive
analgesia.29 Between black and white patients with similar severity of depressive symptoms,
black patients were less likely to be prescribed antidepressant medication. 30 Black and Hispanic
patients were less likely than white patients to receive care in a physician’s office or outpatient
setting, while hospital and emergency room care were the same in all groups. 31 In a qualitative
study assessing clinician’s views toward racial disparities in health care, one physician stated that
racial/ethnic minority patients were less likely to be adherent to taking their medications and
therefore she was less likely to refer her patients to specialists. 32 This is in agreement with the
idea that if patients show mistrust, have poor compliance, or refuse treatment, they may not
receive more specialized services.25 This may become a circular response to one another’s
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attitudes, but undeniably the provider is in the more powerful position and should be looked at
for targeted interventions.25
Socioeconomic factors also play a role in physician decision-making. Clinicians may
order fewer tests or choose a different medication strategy based on economic status and
insurance coverage.24 Care may even be delayed care due to an assumed financial burden on the
part of the provider.24 In a cohort of women over 50 years old, those with lower educational
attainment and household income were less likely to receive a physician recommendation for
mammography.33 Unfortunately, these adjustments in patient care may result in lower quality
services compared to patients with more flexible schedules and the means to pay for their care
and transportation. Patients with no insurance tend to have cancer diagnosed when it is at a later
stage.34 Patients with private insurance receive better primary care, in terms of first contact,
longitudinality, comprehensiveness, and coordination, compared to the publicly insured; and the
publicly insured received better care than the uninsured. 35 In a focus group setting, black patients
have voiced concerns about discrimination and preferential treatment based on financial status
and insurance coverage.36 It is unknown how many people in need of a heart transplant are
excluded due lack of referral of uninsured patients. 26
Other areas of implicit bias include gender, age, and patients that are obese. 37 Females
with similar symptoms and health history as men were less likely to be diagnosed with COPD. 38
Age has an effect on treatment decisions, as older patients have been less likely to be referred for
diagnostic procedures39 or prescribed beta-blockers after myocardial infarctions40 when
compared to younger patients. Clinicians specializing in obesity who took the Implicit
Associations Test were found to associate obese patients with negative stereotypes such as being
lazy, stupid, or worthless.41
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Additionally, the intersection of any of the above factors can have an effect on access to
healthcare. Race is likely a surrogate for other patient factors which affect access to healthcare
services and patient outcomes.42,43 Socially vulnerable groups often face a “chain of events” that
lead to poor outcomes, which can include limitations with education, transportation, health
literacy, social support and results in reduced access to healthcare, poor compliance, diet, or
lifestyle choices.44
Limited English language fluency may also influence access to health care services, as
well as trust in the medical system, the cultural competence of physicians, and the lack of
representation in clinical trials.45 The intersection between race and socioeconomic factors is
revealed when looking at rates of insured individuals stratified by race. According to the United
States Census Bureau report from 2020, people of Hispanic origin had the highest uninsured rate
at 18.3%.46 The uninsured rate for black, Asian, and non-Hispanic white individuals was 10.4%,
5.9%, and 5.4%, respectively.46 The higher rates of uninsured individuals in non-white racial and
ethnic groups is an important contributor to limited access to healthcare services in these
populations. As for public insurance coverage, individuals in the black racial group had the
highest rate at 41.4%, with 35.9% of people of Hispanic origin, 33.8 of non-Hispanic whites, and
27.0 of Asian individuals with public insurance. 46 The highest rate of private insurance was in
non-Hispanic whites individuals (73.9%), followed by Asians (72.4%), blacks (54.6%), and
people of Hispanic origin (49.9%).46 As illustrated above, differences in insurance type and
coverage can have an effect on access to services in addition to outcomes, although other unseen
factors are also likely at play.
Conditions of social inequality function as fundamental causes of disease. For instance,
an analysis of tax records from 2001-2014 revealed that higher income was associated with a
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longer life.47 The gap in life expectancy in the United States was 14.6 years between the richest
1% and poorest 1% of men and 10.1 years between the richest 1% and poorest 1% of women. 47
The complex factors contribute to unfavorable outcomes in non-white racial and ethnic groups.
Heart failure patients belonging to non-white racial and ethnic groups tend to have greater
morbidity and mortality.45 Higher rates of comorbidities such as hypertension, diabetes, chronic
kidney disease, and obesity in black heart failure patients compared to white heart failure
patients have been noted in the literature. 48
Patient involvement is an essential part of the clinical decision-making process. 24 In
qualitative studies, clinicians have shared through interviews that improved patient-clinician
relationships occur when clinicians are willing to understand a patient’s culture, can comminute
using the patient’s language, and works with the patient toward treatment goals. 28 The extent to
which health care disparities affect the utilization of technologies is the crux of the proposed
research.

Patient Decision-Making
Access to healthcare services and utilization of services are not interchangeable terms. 49
Patients may decline healthcare services for personal, cultural, religious, or socioeconomic
reasons. Socially reinforced roles may influence patient decision-making in terms of choosing to
undergo a medical treatment.
Research has demonstrated that women turn down medical treatments more often than
men, for example, women who were eligible for heart transplantation were more likely to refuse
transplantation than men despite recommendation that it was the best therapeutic option. 50 A
potential reason for this refusal is the ubiquitous role women play when it comes to reproductive
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labor. Women are more likely to take on the childcare, cooking, and cleaning responsibilities of a
household than men.51 Advanced heart failure therapies such as transplantation and LVAD are
life-changing with regards to follow-up care, lifestyle changes, and lifelong medications, which
may not be feasible for women more than men due to reproductive labor.
Socioeconomic factors also play a role in patient decision-making. Patients who refused
heart transplantation were more likely to have insurance coverage through Medicaid, Veterans
Affairs, or workers’ compensation compared to patients who had commercial insurance, health
maintenance organization, or Blue Cross/Blue Shield insurance that did not refuse. 50 The
financial burden may be too much for some patients to choose the best therapeutic option, with
patients in economic hardship choosing comfort care over life-extending measures. 52 Further, if
employed patients miss work due to their heart failure symptoms, they may lose their eligibility
for insurance coverage and therefore may not be able to get the healthcare they require. 26
Regional differences in the availability of primary care are an important aspect of patient
access. Of particular importance to this research is the ability to have continuity of care, from a
primary care physician to a cardiologist, to an AHF specialist. This continuity varies regionally
and is essential in obtaining an appointment with a specialist. 11 Lack of a primary care physician
affects likelihood of referral, since the evaluation and referral process requires follow-up visits
and an ongoing discussion of symptoms with the provider. Therefore, lack of an appropriate
provider or specialist is one’s area could be problematic, especially for those with transportation
limitations or scheduling hurdles with work and childcare. 11
Patient trust in the healthcare system also affects decision-making. This is particularly
true for black patients. Some are afraid, whether conscious or not, that white medical providers
will subject them to experimentation.11 The fear stems from events such as the Tuskegee syphilis
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study53 and still exists today. Focus groups have revealed that black patients have concerns about
potential experimentation in medical settings.36 Other qualitative research has suggested that
racial and ethnic minority patients have lower levels of trust in the health care system, spiritual
beliefs that guide decision-making, and fear of procedures. 28 In addition to the Tuskegee atrocity,
mass incarceration, immigration raids, and police killings have all contributed to peripheral
trauma for minority populations and may impact trust in the medical system. 54
As mentioned above, race is inextricably intertwined with class and gender. In seriously
ill patients, non-white patients were more likely than white patients to suffer from a loss of their
family savings that white patients.52 Race shapes social encounters as well as educational and
economic opportunities in ways that affect emotional, mental, and physical health. 43 Black
patients in focus groups have stated that they want their physician to trust them regarding what
they feel about their health.36 The Kaiser Family Foundation reported that as of 2019, nonelderly
adults of American Indian and Alaskan Native, Hispanic, Native Hawaiian and Other Pacific
Islander, and black racial and ethnic groups were less likely to have health insurance compared
to the white nonelderly population.55
Perceptions of illness severity may impact decision-making, and vary with culture, race,
or ethnicity. In a community telephone survey, non-white respondents and those with lower
socioeconomic status were less likely to know symptoms of a heart attack. 56 Therefore, patients
of racial and ethnic minority may delay seeking medical care due to lack of recognition of
coronary artery disease symptoms.11
The patient’s comprehension of the risks and benefits to certain treatments also play a
role in decision-making. Acceptability of risk may vary for patients, in addition to views about
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quality of life and future life expectancy. Some patients may refuse treatment to preserve their
current quality of life, even if that goes against the medically optimal treatment. 24
The refusal, or unaffordability, of treatment may ultimately be detrimental when a patient
is too sick to receive appropriate care. For example, since women who saw a primary care
physician were more likely to undergo mammography for cancer screening, 57 those women who
did not see a primary care and therefor did not receive a cancer screening may one day be
ineligible for AHF services should they get cancer.

Advanced Heart Failure Services
Patients who have been referred for a visit with an AHF specialist must face a complex
evaluation process with restrictions on the availability of life-saving services. The process
outlined in this section illustrates the complexity of care and hurdles every patient with heart
failure must face.
Donor organs are a limited resource and there is a national allocation system in place to
guide the distribution of organs to suitable candidates. The United Network for Organ Sharing
(UNOS) is a private, non-profit organization under contract with the federal government and
administers the Organ Procurement and Transplantation Network (OPTN). The National Organ
Procurement Act (NOTA) was passed in 1984 and mandated the creation of an OPTN to manage
the allocation of all donor organs in the United States. All organ procurement organizations and
transplant centers must be OPTN members. Patients in need of a donor organ must be added to
the OPTN national waitlist in order to be eligible to receive a donor organ. 6 According to NOTA,
the national allocation system must be both efficient and equitable. 4

17

Transplant centers are responsible for selecting patients to place on the transplant waiting
list. Before a patient is deemed to be an eligible candidate for a donor organ, the patient must
undergo an extensive evaluation process at their transplant center. Since both heart transplant and
LVAD recipients require lifelong medical adherence and pharmacological care, there is a
selection process to determine candidacy for either intervention. Medical, surgical, psychosocial,
and financial eligibility must be determined in order to become a candidate for heart transplant or
LVAD. Eligibility decisions are based on medical need but are also based on selecting patients
who are likely to have a successful transplantation without a high risk for mortality or adverse
events. The psychosocial evaluation is an important step in determining candidacy due to the
major lifestyle changes patients of either advanced therapy must undergo. The assessment is
necessary to determine whether there are concerns with medical adherence, social support,
mental health, substance use/abuse, and cognition which may inhibit a patient’s success postintervention. The assessment also identifies patient risk factors that may be modified in an effort
to improve patient outcomes before the patients is eligible for transplant or LVAD. 58
Each transplant center determines their own criteria for the transplant waitlist. Many
organizations recommend psychosocial evaluations for transplant eligibility there are no
regulations dictating the candidate selection process at each transplant center. OPTN bylaws
state that transplant centers are required to employ trained professionals to conduct the
psychosocial evaluations of potential candidates59 The Centers for Medicare and Medicaid
Services (CMS) advise that a psychosocial evaluation of potential transplant recipient occurs
when possible.60 A consensus paper from groups such as the International Society for Heart and
Lung Transplantation (ISHLT), Academy of Psychosomatic Medicine (APM), American Society
of Transplantation (AST), International Consortium of Circulatory Assist Clinicians (ICCAC),

18

and the Society for Transplant Social Workers (STSW) has provided some guidance on patient
selection, naming adherence, mental health history, and substance use history as risk factors for
poor outcomes for heart transplant or LVAD recipients. 5 The recommendations for the
psychosocial evaluation are based on the need to assess for risk factors that may predict posttransplantation and post-LVAD implantation outcomes; obtain information related to a patient’s
decision-making capacity regarding transplant or LVAD implant; obtain information about
personal, social, and environmental characteristics that could reduce the impact of how their
psychosocial risk factors affect post-transplantation and post-implantation outcomes; and
specific MCS-related evaluations related to a patient’s ability to operate the equipment. 5 The
guidance document also suggests that the transplant and LVAD care teams should provide tools
and interventions to high-risk patients in an effort to improve outcomes, but implementing and
improving likelihood of candidacy of underserved populations is up to the care team at each
institution.
While there are no regulations outlining the psychosocial evaluation requirements, CMS
requires that transplant programs track and report their institutional outcomes which are then
taken into account by CMS when determining conditions of hospital participation. 60 As Boyum
et al. pointed out, herein lies an incentive for transplant centers to select low-risk patients for
transplantation in order to maintain CMS coverage for their transplant program. 61

Social Support
The ISHLT/APM/AST/ICCAC/STSW guidance document states that lack of social
support is a contraindication to heart transplantation and MCS implantation. 5 Social support is
considered a requirement to improve the likelihood of patient adherence to their complex
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medical needs. In this context, social support means that the patient has available, stable, and
capable individuals to provide support for their medical care and emotional needs. 5 Social
support has a particular importance for VAD patients who must adjust to a new way of life with
the implanted device. The available research on social support highlights this concern. In a
prospective study of heart, liver, and lung transplant candidates, lack of pretransplant social
support was a predictors of post-transplant nonadherence. 62 This study also demonstrated that
lack of a partner, such as a spouse or living with a stable significant other, was a predictor of
graft loss between six and twelve months.62 Not only the presence of a caregiver but the
relationship of the caregiver has an effect on survival, as shown in two studies. 63,64 Mollberg et
al. demonstrated that lung transplant recipients with spousal caregivers had increased rates of
survival compared to patients with a sibling or adult child as a caretaker. 63 Similarly, an analysis
of heart transplant recipients revealed improved 1-year and 5-year survival in married patients
compared to patients with children and/or grandchildren. 64
In a 2016 survey of thoracic transplant professionals, 85% of respondents felt that
patients with higher socioeconomic status were more likely to have adequate social support
compared to patients with a lower socioeconomic status, and 93% of respondents considered
adequate social support to be a fair requirement. 65 These findings shed light on the inequity of
the transplant evaluation process, as the current system reduces the likelihood of those with
social and economic disadvantages becoming eligible for heart transplant or LVAD.

Economic Factors
The use of insurance coverage as a requirement for transplantation and LVAD has been
controversial, and many transplant professionals believe it should not be used to determine
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eligibility.26,66 Even though the World Health Organization states in their Guiding Principles on
Human Cell, Tissue and Organ Transplantation that organ allocation should not be based on
financial circumstances,67 few patients that are underinsured or without insurance receive a
transplant7 or even undergo an evaluation.26 Specifically, public insurance has shown to be
associated with reduced access to advanced therapies. A single center review of advanced
therapy evaluations indicated that patients with Medicare or Medicaid were less likely to be
eligible for a transplant when compared to privately insured patients. 8 An analysis of the
nationwide inpatient sample demonstrated the private insured to have the highest rate of
utilization amongst LVAD recipients.68 One reason for reduced eligibility is that many public
insurance plans only offer partial coverage and multiple Medicare coverage plans are required
for eligibility at many programs.69,70
Less favorable outcomes among the publicly insured are well documented in the
literature. A single center chart review showed that Medicaid insurance was associated with
increased risk of one-year mortality in patients ineligible for AHF therapies. 8 In two separate
analyses of the UNOS database, Medicare and Medicaid insurance were shown to be predictors
of mortality in heart transplant recipients.71,72 An analysis of the Scientific Registry of Transplant
Recipients of heart, liver, lung, and renal recipients demonstrated that patients with Medicaid
insurance had significantly lower rates of survival compared to the privately insured. 73 Patients
with public insurance, and patients who transitioned from private to public insurance, have been
demonstrated to have increased rates of mortality on year after heart transplantation. 74 Waitlist
mortality is also worse amongst BTT LVAD patients with Medicaid coverage compared to those
with private insurance.75 Poor outcomes in patients of lower socioeconomic status may be the
result of limitations in the financing of healthcare services in the United States. 5,76 Previous
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investigators have noted that access to follow-up care and coverage of immunosuppressive
medications may contribute to higher mortality rates in the publicly insured. 71 Medicare requires
a 20% copayment for immunosuppressive medications which may not be feasible in the longterm for some patients.77 Barriers to access likely cause delays in treatment, and publicly insured
patients with AHF may be evaluated for advanced therapies in a more advanced disease state
compared to the privately insured. Such delays could have a direct effect on the success of
transplantation or LVAD implantation.
Other socioeconomic factors have been shown to affect outcomes in patients with a heart
transplant or LVAD. In an analysis of the UNOS data, Allen et al showed that a college
education decreased the risk of mortality by 11% compared to patients without a college
education,71 and Wayda et al demonstrated a college education reduced mortality by 18% in a
separate analysis of the UNOS data.72 Another analysis of UNOS data showed that among heart
transplant candidates, those who lived in counties with higher concentrations of household
incomes greater than $75,000 had a lower risk of mortality compared to candidates living in
counties with high concentrations of income below the Federal poverty line. 78 Yet another study
analyzed patients from the UNOS registry, but this time calculated the Agency for Healthcare
Research and Quality socioeconomic index, and found that patients within the lowest
socioeconomic index quartile had an earlier and increased risk of post-transplant mortality
compared to patients in each of the other quartiles. 79 In a study which assessed the self-reported
financial status of patients with heart failure, those with lower financial status were more likely
to experience a cardiac event in comparison to patients with a higher financial status. 80 Another
study utilizing census-based socioeconomic indicators demonstrated an inverse association
between cardiovascular disease mortality and education, income, and occupation amongst
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patients in the National Longitudinal Mortality Study. 81 Among middle-aged, healthy study
participants with higher than average socioeconomic status, those that were unemployed were
more likely to have a cardiovascular event.82 While employment status has been used as a
predictor of poor health and mortality, it is possible that those with poor health are more likely to
become unemployed.83 Lower household income has also been shown to be associated with
rejection for heart transplant candidacy.50
Due to the insufficient coverage for heart and transplantation and LVAD implantation by
the country’s healthcare system, some have argued that the financial burden and hardships placed
on recipients and caregivers may be too much for some patients and should be avoided. 66 The
ethical consequences of such a decision must be considered. Denying organs based on financial
eligibility has moral implications, as it is unjust that the uninsured can donate organs but may be
unable to receive an organ if they are in need of a transplant.26,84 A survey of transplant
professionals from 2013 revealed that only 6% of transplant programs participate in fundraising
efforts for patients with insufficient resources. 7 However, it is likely that socioeconomic status,
specifically public insurance, is a surrogate for other personal and environmental characteristics
that affect a patient’s disease trajectory and outcomes.

Substance Abuse
Substance abuse is another contraindication for transplant and LVAD implantation due to
concerns with patient compliance with the medical regimen resulting in poor patient outcomes.
Substance use has been shown to be associated with non-compliance and adverse outcomes in
heart transplant recipients.85 For substance use such as tobacco, alcohol, and marijuana, each
transplant program develops their own criteria for the risk associated with eligibility, while illicit
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drugs are absolute contraindications. Transplant programs often require a period of sobriety
before candidacy for advanced therapies in order to reduce the likelihood of relapse in the posttransplant period.
Previous research has shown that substance use and abuse is associated with poor
outcomes in heart failure patients. A single center, retrospective review found that smoking was
associated with an increased risk of one-year mortality among LVAD recipients who were
smokers at the time of admission for LVAD implant. 86 An analysis of the Interagency Registry
for Mechanically Assisted Circulatory Support (INTERMACS) registry revealed that 1,941
(12.6%) of 15,403 LVAD recipients had substance abuse (either alcohol abuse or drug use) listed
as a psychosocial risk factor.87 Both alcohol abuse and drug use were associated with devicerelated infection and hospital readmission, while only drug use was associated with device
thrombosis and only alcohol use was associated with gastrointestinal bleeding. 87
Due to differing attitudes and regional differences in legality, marijuana use may or may
not be prohibitory to eligibility by transplant centers. In some states, laws have been passed to
protect patients bring denied a transplant based on medical marijuana use, 88 but opinions
regarding marijuana use and eligibility vary widely in the transplant community with some
believing there is not enough research available to understand the risks involved. 89 Of transplant
professionals surveyed in 2015, 64.4% felt that legal marijuana use should be allowed in
transplant candidates, but 65.7% of respondents considered marijuana to be physically harmful. 90
A 2016 survey of the American Society of Transplantation members revealed that most (72%)
respondents were concerned about the association between fungal complications and marijuana
use, although less than half of those respondents reported observing fungal infections that they
considered attributable to marijuana use.91 Other possible adverse effects of marijuana use that
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are of concern include drug-drug interactions, pulmonary disease, cardiovascular disease, renal
disease, gastrointestinal disease, addiction, and neuropsychiatric disease, although there is
limited clinical data available on how marijuana use affects outcomes in organ transplantation. 92
Variability between transplant program in the philosophical approach to substance use
eligibility for advanced therapies is problematic. Such variability creates disparities in access to
an inherently limited resource and therefore calls for a universal standard defining substance
abuse, expectations of abstinence, testing standards, and action plans for patients have been
made.89 It has been speculated that patients with a history of substance use and/or abuse may not
be viewed as favorably as patients with other behaviors such as sedentary lifestyle, morbid
obesity, poor dietary choices, non-adherence, and altered mental status. 92 Improving candidacy
of patients who have a substance use or abuse history is important, as these patients are able to
contribute to the organ donor pool but may be unable to receive a transplant if medically needed.
Uniform practices for assessment and treatment of patients with substance use which prevents
them from advanced therapy eligibility could improve equity for such patients across all
transplant programs.

Depression and Mental Illness
Uncontrolled psychiatric conditions that affect medical adherence are a contraindication
to heart transplantation and LVAD implantation.5 Therefore, the psychosocial assessment is
important for understanding a patient’s mental health history as well as previous and current
treatments. Understanding risk factors is essential for offering appropriate treatments to potential
candidates who are medically eligible for AHF treatments.
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The available evidence on research examining patients with AHF patients and mental
health diagnoses show less than ideal outcomes.93–95 Previous research has shown depression to
be associated with poor health outcomes post-transplantation, with a prospective study revealing
patients with depression and social isolation at the time of listing had lower post-transplant
survival compared to patients without depression and social isolation at time of listing. 93 A single
center analysis of psychosocial risk factors demonstrate that current depression disorder and
history of a suicide attempt were predictors of shorter survival time in heart transplant
recipeints.94 In a meta-analysis, Dew et al. found a 65% increase in mortality risk among patients
with diagnosed depression.95
However, not all heart transplant recipients with depression have poor outcomes. In a
single center retrospective review, Delibasic et al. found that patients with depression had similar
survival rates, number of organ rejections, and compliance with outpatient appoints compared to
patients without depression.96 The patients with depression had a higher number of
hospitalizations post-transplant as well as a higher number of admissions due to infection.
Another single center study showed no difference in survival, time to first hospitalization, and
rejection rates between patients diagnosed with depression and those without depression. 97 All
patients with depression were treated with antidepressant medications or psychotherapy before or
within of year of transplantation. Transplant recipients at the Veterans Health Administration
(VHA) who had severe mental illness did not have increased mortality or post-transplant
complications compared to patients with other mental illness or without mental illness. 98 The
mental health services offered at the VHA may contribute to the post-transplant outcomes.
Further, in their review of the effect of affective and psychotic disorders on transplant
eligibility, Cahn-Fuller and Parent99 describe published reports of patients with psychotic
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disorders including schizophrenia who have had successful transplants. 100–102 As Cahn-Fuller and
Parent summarized, the positive outcomes were likely due to the extensive, individualized
psychiatric care that these patients received. Further, differences in candidate selection criteria
and the heterogenous psychiatric population make comparisons between practices at different
transplant programs difficult. Therefore, generalizations about psychiatric illness and success
after transplantation cannot be made.
While there is not enough research to confirm transplantation is appropriate in patients
with psychiatric disorders, there is not enough evidence to prohibit patients from AHF therapies
based on psychiatric conditions. As stated by Cahn-Fuller and Parent, post-transplant outcomes
are likely the result of multiple factors in addition to psychiatric illness, including inadequate
social support and medical noncompliance, and selection processes that exclude psychiatric
patients are unjust.99 The authors of that review suggested that the assessment of noncompliance
is more important than presence of psychiatric illness and call for future research identifying risk
factors of noncompliance. The variability in outcomes post-transplant demonstrate the need for
interventions early in the heart failure disease trajectory.
Cognitive behavior therapy (CBT) interventions showed promising results in a
prospective randomized controlled study including patients who had a heart failure diagnosis, a
current major depressive episode, and a depressed score on the Beck Depression Inventory. 103
Patients were randomized into groups that received CBT or usual care, and those in the CBT arm
had lower score for depression at six months, in addition to improved scores for anxiety, heart
failure-related quality of life, mental health-related quality of life, fatigue, and social
functioning.103 These findings emphasize that psychiatric diagnosis alone should not be
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prohibitive to transplantation, and interventions should be offered to those who may be eligible
but require additional support.

Gender-Related Factors
Of the over 6.2 million Americans with heart failure, over half are women. 18 Research
has demonstrated that heart disease manifests differently based on sex, with different symptoms,
including more complex and multifactorial signs in women than in men. 104 Complex factors are
involved, but one reason is that the presence of estrogen acts as a protective factor against heart
disease.105 Current research indicates that in general, women with heart failure have better
survival than men with heart failure.45 Men are more likely to experience a cardiovascularrelated cause of death than women.106,107
At the advent of LVAD use, women were rarely enrolled in clinical trials because early
versions of LVADs were too large for many female bodies. 22,108,109 LVAD recipients tend to be
younger and male compared to heart failure patients without an LVAD. 68 A review of the UNOS
database found that while LVAD use in women has increased over the years, the rate of LVAD
at listing remains significantly less in females (4.3% in 2008 and 18.9% in 2017) compared to
males (5.0% in 2008 and 29.9% in 2017) (p<0.001).110 LVAD use in males may be reflected by
the conventional use of LVADs in men due to larger body size, despite the decrease in LVAD
size over the years.22,68 The available data suggests that there is no difference in survival rate
after LVAD implantation between men and women, 111,112 but women had greater risk of first
neurological event,112 longer length of stay, and higher incidence of right-heart failure, renal, and
respiratory dysfunction.111 The differences in adverse events may be due to the fact that women
are referred for AHF therapies when their heart failure is at a more advanced disease state. 109
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Women receive heart transplants less frequently than men, with 28.4% of the available
hearts going to women and 71.6% going to men in 2017. 2 Heart transplantation in women has
increased over the years, with women accounting for 19.7% of the total heart transplantations
occurring in the years 1992-2000 and 23.7% in the years 2006-2011. 113 However, women are
more likely than men to refuse a heart transplant after they were determined eligible
candidates.50 These findings suggested that patient choice, rather than physician bias, was the
reason behind fewer women receiving heart transplants.

Influence of Race and Ethnicity
The federal government has classified race into 5 categories (American Indian or Alaska
Native, Asian, black or African America, Native Hawaiian or Other Pacific Islander, and white)
and ethnicity is divided into two categories (Hispanic or Latino, or not Hispanic or Latino). 114
While heart failure affects all populations, limited research is available on non-white
populations. Non-white races and ethnic groups are underrepresented in clinical trials, making it
difficult to understand the applicability of many research studies to non-White populations.
An analysis of the nationwide inpatient sample database revealed that while the majority of
LVAD recipients were white (78.5%), the rate of utilization was highest in Black patients
(1.04%), compared to 0.89% in White patients.68 However, available data shows the Black and
White patients have similar outcomes after LVAD implantation. 115 White patients are more
likely to be candidates for heart transplantation than non-White patients. 50 Interestingly,
prospective research investigating the development of cardiovascular disease showed that Black
patients were more likely to develop heart failure before the age of 50 compared to White
patients.48 While Black heart failure patients had more episodes of rejection and more
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hospitalizations compared to White patients, however there was no difference in mortality after
heart transplantation between the two racial categories. 116
Patients in the Hispanic ethnic group are the most affected by risk factors for heart
failure, such as diabetes, being overweight or obese, atherogenic dyslipidemia, metabolic
syndrome and insulin , and poorly controlled hypertension. 117 Compared to non-Hispanic whites,
Hispanics have been shown to have higher rates of hospitalization and readmissions but rates of
in-hospital and short-term mortality were lower. 117 The increase in hospitalizations may be the
result of limited access to preventive care due to Hispanics having high rates of uninsured
individuals. Language barriers may also contribute to reduced access to preventative care. A
report from the Pew Research Center stated that 11% of Hispanics in the U.S. over the age of 5
(over 5.5 million individuals) did not speak English proficiently as of 2013. 118
As discussed above, lack of trust in the medical system is another reason for the
differences in access and outcomes between racial and ethnic groups. Black persons have been
subjected to exploitation within the medical system, a notable example being the Tuskegee
syphilis study.53 It is therefore expected that there would be mistrust in the medical system. This
mistrust has likely contributed to less black organ donors as the health care system is not viewed
as equitable.119

Age
The lifetime risk for heart failure is high in older adults, at 20-45% for individuals 45 to
95 years old.18 A number of age-related changes in the physiological cardiac characteristics may
contribute to the increased risk of heart failure as we age, including decreased numbers and
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function of cardiac muscle cells, impaired regenerative functions, buildup of amyloid protein in
the heart, and increased risk of hypertension. 45
The management of heart failure in older patients is different from that in younger
patients. Older adults have an increased number of comorbidities which can complicate
management of their heart failure.45 Older adults are not often treated with transplant or LVAD,
and some institutions have upper age limits for transplant eligibility. Seventy years old has been
the historical cut-off, but as care has improved, more patients ≥70 years old have been
transplanted with good outcomes.120 The decision between aggressive treatment for heart failure
or maximizing quality of life is a decision for the individual patient. Like the other groups
mentioned above, older adults are less represented in clinical trials, therefore making evidencebased practices less applicable to this group.
Age is a key factor predicting mortality in heart failure patients, likely due to increasing
numbers of noncardiac comorbidities.45 An analysis of nation-wide heart failure hospitals
revealed the youngest (less than 25 years old) and oldest (over 64 years old) patients had the
greatest rates of in-hospital mortality.121 Older LVAD recipients have higher risks of
complications and mortality, however older heart transplant recipients had similar rates of
survival as younger recipients.122

Structural Barriers
A multitude of factors affect any person’s access to healthcare services, although certain
barriers are considered the result of systemic biases that have existed for hundreds of years.
Scientists as far back as the 1600s have contributed to the myth of White male superiority, with
the publication of the first scientific article on racial classifications and has continued over the
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centuries.25 The Atlantic slave trade, together with European colonization and Eurocentrism,
were global events that has seemingly limitless repercussions on racial, class, and economic
disparities to the present day.123 In the American English colonies, the health system was formed
on an inherently biased structure based on race and class. 25 The hierarchy against non-White
persons, immigrants, and women in the scientific and medical arenas persisted into the 20 th
century with those populations being excluded or marginalized by the healthcare systems. The
move toward desegregation in healthcare culminated with the Civil Rights Act of 1964 124 but this
did not end discrimination. Racial, ethnic, gender, and class-based biases and inequities have
prevented minorities from accumulating wealth, inhibited access to care, and created gaps in
health status and outcomes. These divides have been promoted by limitations in government
funding for Medicare and Medicaid.
Unraveling healthcare discrimination from the disproportionate poverty levels 125 and
uninsured rates46 in racial and ethnic minorities is difficult if not impossible. Income rates as of
2019 for Black households was 60% of that of White households, and Hispanic households had
an income rate 74% of that of White households.125 As stated in the 2008 documentary,
Unnatural Causes, wealth equals health.126 The two are inextricably linked in the United States,
with income affecting access to housing, neighborhoods, employment, transportation, childcare,
schools, and hospitals. The disparities will be passed to the next generation, with even wider
income inequality and less opportunity for mobility in future generations, a phenomenon called
The Great Gatsby Curve.127 While accounting for systemic inequality is outside of the scope of
this research, it is important to keep in mind the factors influencing the current inequities in
access to healthcare services.
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Ethics
In the United States, organ allocation is based on algorithms determined by UNOS
policy-making practices.128 The allocation algorithms take into account efficiency and equity,
which are required for organ distribution by Federal law.4 These two terms are equivalent to the
ethical principles of utility and justice.84 When it comes to organ allocation, utility is commonly
thought of as medical benefit and refers to allocation practices that maximize the benefit to
patient as well as the whole community while also reducing harms. 129 Therefore in this case,
utility combines the principles of beneficence and nonmaleficence. OPTN considers the principle
of justice, defined as the fair distribution of benefits and burdens, to be equally important to the
principle of utility in organ allocation.129 While donated organs should be allocated to maximize
overall good, ethicists such as Robert M. Veatch and Lainie F. Ross argue that when it comes to
scarce resource allocation, justice has moral authority over utility. 84 According to Veatch and
Ross, just and morally correct distribution follows a pattern of equal access. A notable
interpretation of the principle of justice has been made by John Rawls, 130 whose egalitarian view
of justice allows for a redistribution of goods to maximize the potential advantage for the most
disadvantaged persons. This view avoids making distributive decisions based on arbitrary
characteristics, such as social or economic advantage, accident of birth, or natural talents. 131
The equitable, or just, distribution of goods to promote the maximum advantage for the worst-off
persons is distinct from the equal distribution of goods. Therefore, equitable distribution requires
that we account for the principle of justice.
Since equity in allocation is agreed upon for the distribution of both transplant and
LVAD AHF services, the current research theorizes that the concept of justice should be just as
important in the distribution of healthcare services before a patient is ever evaluated for AHF

33

therapies. The UNOS and OPTN policies, which are required to be efficient and equitable, only
apply to patients that are determined to be eligible for transplantation. However, if a patient
never has the opportunity to be evaluated by an AHF specialist, or even be referred for an
appointment, inequity in allocation is already present before allocation ever occurs. Therefore, in
order to improve disparities in the health, the practices leading up to heart transplant candidacy
must also be equitable.
The structural barriers described above contribute to the disadvantage of certain
populations, such as those lacking financial resources, and promote inequity in allocation. The
strong association between race and poverty described above perpetuates the withholding of
transplants from disadvantaged populations.132 The current practices reveal that justice is not
weighed equally in the current policies and practices promoted by UNOS and OPTN.
Another area of ethical concern is the variability in eligibility rules and evaluation
practices between providers and institutions which may create inconsistent and inequitable organ
allocation. There is limited information on how psychosocial evaluations vary between transplant
programs, and what is available is from the early 1990s. 133,134 Unfortunately, that data is likely
outdated due to being is approximately 30 years old. While it is presumed institutions are abiding
by the guidelines issued by ISHLT and other organizations, there is no overarching requirement
in place. Cahn-Fuller and Parent have questioned the extent to which transplant programs follow
the recommendations from ISHLT and other professional associations. 99
Disparity in treatment due to variations in rules is problematic, especially for the
allocation of scarce resources. One negative impact from this variability in practices is that it
encourages patients with sufficient resources to be evaluated for advanced therapy at more than
one transplant center. Such “shopping” 89 for transplant programs creates disparities in access to
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donated organs. Further, the principle of justice is abandoned as these practices create an unfair
advantage for patients with a higher socioeconomic status. Therefore, calls have been made for a
standard set of selection criteria to avoid such variation. 99
Reciprocity of the donor pool is an important area to consider when examining the
evaluation practices leading up to the allocation of donated organs. Various groups, including
psychiatric patients99 and the uninsured,26 contribute to the donor pool but may not be eligible
should they ever medically require one. Asking a population to contribute to the donor pool
when they would be considered ineligible violates the principle of justice. 26 These populations
deserve access to organs when in need and there is a moral obligation to fairly consider these
populations if they are in need of an organ. Donated organs are a public resource, and altruistic
organ donors expect that organs will be distributed equitably. 26
While inequities exist throughout the healthcare system, the need for a just assessment of
heart failure patients at each step in the evaluation process is amplified when looking through the
lens of organ scarcity. The proposed research argues that since practices surrounding the
distribution of donor hearts must be just, so should the evaluations process of patients who one
day may need the services of an AHF team. Judgments about a patient’s social worth should be
avoided.99

Summary
For some patients with AHF, the only medical option is a life-saving heart transplant or
LVAD. A patient with AHF must go through an extensive evaluation process in order to be
determined eligible for such advanced therapies. Demographic, social, and economic factors all
play a role in that determination process. When these factors play a role in the eligibility for AHF
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therapies, healthcare resources are not distributed equitably. While some of the factors playing a
role in eligibility have been researched, there are likely unseen factors beyond the scope of this
research that also contribute and have not been properly captured and analyzed. Understanding
whether certain factors affect a patient’s ability to receive services earlier in their disease
trajectory, just after they display heart failure symptoms and receive a diagnosis, is the basis of
the proposed research.
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CHAPTER III
METHODOLOGY
Approach
This is a retrospective chart review of electronic medical records (EMR) available at a
large, Midwest hospital system over a four-year period. This study investigated how
demographic, social, and economic factors influence the referral of patients for advanced heart
failure services and whether those factors affect if patients are seen in the heart failure clinic. The
study also assessed if those factors affect the length of time between diagnosis and referral, clinic
visit, treatment, and/or death.

Study Population
Adult patients from one large, Midwest hospital system who were diagnosed with heart
failure by a provider in the inpatient or outpatient setting, were eligible for this retrospective
chart review. Patients were identified by the presence of heart failure diagnosis codes from the
10th edition of the International Classification of Diseases (ICD-10) in the hospital system’s
EMR. Patients with ICD-10 codes for heart failure (I42.8 [Other cardiomyopathies], I50.20
[Unspecified systolic heart failure], I50.22 [Chronic systolic heart failure], I50.23 [Acute on
chronic systolic heart failure], I50.33 [Acute on chronic diastolic heart failure], I50.42 [Chronic
combined systolic and diastolic heart failure], and I50.43 [Acute on chronic combined systolic
and diastolic heart failure]) between the dates of November 1, 2017 through December 31, 2021
were included in the study. This time frame was chosen to align with the switch of EMR to
Epic135 at our hospital system in November 2017, and the end date aligns with the approximate
date of IRB approval. Patient identifiers were not collected except for dates of service.
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Therefore, this study received a waiver of patient consent as well as a HIPAA waiver due to the
non-human subjects determination by the Spectrum Health Institutional Review Board (#2022034) and the Western Michigan University Institutional Review Board (#2022-096).

Study Design
Demographic, social, and economic data was retrieved by retrospective chart review. To
comply with Spectrum Health research guidelines, data was pulled from the EMR by a specified
Spectrum Health Office of Research employee, called the honest broker. “Honest broker” is a
term used by the Office for Human Research Protections, within the U.S. Department of Health
and Human Services, and is defined as a neutral intermediary person or system that collects
patient information, replaces the identifiers with a code, and then releases only coded
information to the researcher.136 The Spectrum Health honest broker has specific access to the
institutional data warehouse, containing all patient medical record data from the EMR software,
Epic. The honest broker fulfilled the data acquisition from this retrospective review by retrieving
the requested data from the data warehouse, removing all identifiers except dates of service, and
saving in password-protected Microsoft Excel files. The Microsoft Excel files were shared with
the investigator who completed the data cleaning and statistical analysis.
The independent variables selected for this study were based on the above literature
review and specific research questions. Social history and social determinants of health
information (such as employment status, number of children, years of education, highest
education level, alcohol use, drug use, financial resource strain, food insecurity, lack of
transportation [medical or non-medical], physical activity, stress, social connections, depression,
and housing stability) collected from patients either at their primary care office or in the inpatient
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setting should be entered into the EMR; however according to preliminary data queries by an
honest broker, the data for these fields is rarely entered. Smoking status was the only variable
from the social determinants of health documentation that was sufficiently available to include in
this study.
Independent variables collected from the Demographic section of the EMR include age,
sex, race, preferred language, and marital status. As stated above, smoking status was collected
from the social history and social determinants of health sections of the EMR. Type of insurance
was obtained from the EMR documentation. The above variables were captured at the time of
heart failure diagnosis. The categories of some variables had to be combined due to small sample
sizes and to reduce the risk of identification. For the variable, marital status, the categories
married and significant other were combined into one group, and the categories divorced, legally
separated, single, widowed were combined into one “unmarried” group, and patients with
unknown marital status were marked as missing. The category, “Other”, in the race/ethnicity
variable, included such categories as American Indian, Alaskan Native, Asian Indian, Asian or
Pacific Islander, Asian not Hispanic, Chinese, Filipino, Japanese, Multiracial, native Hawaiian,
and Other. The “patient refused/unreported” patients were marked as missing. Preferred
language was categorized into English and non-English language. The category, current smoker,
included patients recorded as current cigarette, cigar, and/or pipe smokers in the EMR, while
non-smokers included both never-smokers and former smokers. Public insurance included both
Medicare and Medicaid.
The dependent variables, referral AHF specialist, clinic visit with AHF specialist, heart
transplantation, LVAD implantation, 1 year mortality, and in-house mortality (post heart
transplant or LVAD) were obtained by electronic abstraction by the honest broker. Dates of
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diagnosis, referral, first clinic visit, heart transplantation, and LVAD implantation required for
the survival analysis were all be electronically abstracted from the EMR.

Analytical Framework
A total of 24,258 patients diagnosed with heart failure from one Midwest hospital system
were included in this research. Independent variables include age, sex, race, preferred language,
marital status, smoking status, and insurance type. Dependent variables include referral to
advanced heart failure services, clinic visit with advanced heart failure specialist, treatment by
either heart transplantation or LVAD, and mortality (1-year mortality post-diagnosis; 1-year
mortality post-treatment; or mortality during hospital stay of heart transplant or LVAD
implantation). For all analyses, values of p ≤ 0.05 were considered statistically significant for all
tests. The ANOVA, Chi Square, and Cox proportional hazards analyses were conducted in SPSS
and the Logistic Regression was performed in R for SPSS.137
The following research questions will be investigated by statistical analysis: 1.) Do
patients who were diagnosed with heart failure and referred for AHF services differ from patients
diagnosed with heart failure and were not referred with regards to demographic, social, and
economic factors; 2.) Do patients who were referred and had a clinic visit with an AHF specialist
differ from patients referred but did not have a clinic visit with regards to demographic, social,
and economic factors; 3.) Do patients who had a clinic visit and received AHF treatment
(transplant and LVAD) differ from patients who had a clinic visit and did not receive AHF
treatment? and 4.) Does the length of time from diagnosis to referral, diagnosis to clinic visit,
diagnosis to treatment, and/or diagnosis to death differ based on demographic, social, and
economic variables?
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Statistical Analysis Plan
1.) Research Question One
a. Independent Variable(s)
i. Patients who were referred visit will be compared to the patients who
did were not referred based on age, sex, race, preferred language,
marital status, smoking status, and insurance type
b. Dependent Variable
i. Referral to advanced heart failure clinic
ANOVA will be used for the continuous variable, age
Chi Squared test will be used for categorical variables: sex, race, preferred
language, marital status, smoking status, and insurance type
2.) Research Question Two:
a. Independent Variable(s)
i. Patients who had a clinic visit will be compared to the patients who
did not have a clinic visit based on age, sex, race, preferred language,
marital status, smoking status, and insurance type
b. Dependent Variables
i. Clinic visit with advanced heart failure specialist
ANOVA will be used for the continuous variable, age
Chi squared test will be used for categorical variables: sex, race, preferred
language, marital status, smoking status, and insurance type
3.) Research Question Three:
a. Independent Variable(s)
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i. Patients who received advanced heart failure treatment (transplant and
LVAD) will be compared to the patients who did not receive treatment
based on age, sex, race, preferred language, marital status, smoking
status, and insurance type
b. Dependent Variables
i. Advanced heart failure treatment (either heart transplant or LVAD)
ii. Heart transplantation only
iii. LVAD implantation only
ANOVA will be used for the continuous variable, age
Chi squared test will be used for categorical variables: sex, race, preferred
language, marital status, smoking status, and insurance type
4.) Research Question Four:
a. Time to event analysis: A Cox proportional hazards model will be used for the
time to event analysis. Hazard ratios with 95% confidence intervals will be
reported.
i. Independent variables:
1. A sensitivity analysis138 will be included in Research Question
4. The sensitivity analysis (as follows) will reveal if there are
hidden suppressor variables that did not show up as significant
in Research Questions 1-3 or if there is no or little influence on
the conclusions of Research Questions 1-3, which would
provide more robust conclusions.
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a. First, only the independent variables that were found to
be significant in Research Question 1, 2, and 3 will be
examined evaluated by Cox proportional hazards
model.
b. Next, all independent variables (age, sex, race,
preferred language, marital status, smoking status, and
insurance type) will be assessed in a Cox proportional
hazards model.
ii. Dependent variables
1. Survival analysis will be used to evaluate:
a. time from diagnosis to referral
b. time from diagnosis to clinic visit
c. time from diagnosis to advanced heart failure treatment
b. Mortality
i. Independent Variables
1. A sensitivity analysis will be done similarly as described in
Research Question 4. First, only the independent variables that
were found to be significant in Research Question 1, 2, and 3
will be examined by Logistic Regression
2. Next, all independent variables ((age, sex, race, preferred
language, marital status, smoking status, and insurance type)
will be assessed by Logistic regression.
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a. Death within one year post heart failure diagnosis
(yes/no)
b. Death before discharge from heart transplant or LVAD
implant hospital stay (yes/no)
c. Death within 1 year of heart transplant or LVAD
implant (yes/no)
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CHAPTER IV
RESULTS
There were 24,258 patients diagnosed with heart failure included in the analysis (Figure
1). The mean age was 71.47 and ages ranged from 18 to 106 years old (Table 1). Patients were
mostly male (58.7%), married (51.5%), White (88.1%), had preferred language listed as English
(98.6%), and had public insurance coverage (81.2%). Of the 7,238 patients with smoking data
available, 1982 (8.2%) were current smokers at the time of diagnosis. Of the patients diagnosed
with heart failure, 617 (2.5%) had a date of referral to see a heart failure specialist documented in
the EMR.

Referral
A total of 617 patients received an AHF referral. Research question 1 compared the
independent variables between the referral group and non-referral group (Table 2). The ANOVA
analysis revealed that patients referred to an advanced heart failure specialist were younger than
patients who were not referred (mean age 57.84 vs 71.83, p<0.001). Over twice as many men
were referred, with 3.2% of the men and 1.5% of the women with heart failure having a referral
(p<0.001). Married patients were more likely to be referred than the unmarried patients (2.9% vs.
2.1% respectively, p<0.001). Race was significantly associated with referral (p<0.001), with
White (2.3%) and Hispanic/Latino patients (2.4%) showing less referrals than Black patients
(4.3%) or patients in Other racial categories (4.8%). There was no difference in referral based on
preferred language (p<0.828) or smoking status (p=0.057). Insurance category was associated
with referral (p<0.001), with the most referred category being the publicly insured, followed by
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Diagnosed with heart
failure
n = 24258

Referred to advanced
heart failure clinic

Not referred to advanced
heart failure clinic

n = 617

n = 23641

No clinic visit with
advanced heart failure
specialist

Clinic visit with advanced
heart failure specialist
n = 409

n = 208

Received advanced heart
failure treatment

No heart failure
treatment

n = 111

n = 298

Received heart
transplantation
n = 57

Received LVAD
n = 64

Figure 1. Flowchart of patients diagnosed with heart failure

privately insured, then self-pay (Table 2). Since zero of the 7 patients in the Other insurance
category were referred, this category was removed from the analysis.
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Table 1. Summary of baseline characteristics for all patients diagnosed with heart failure
Variable

Category

Age (years)
Sex
Marital Status

Race/ethnicity

Preferred Language
Current smoker
Insurance

Female
Male
Divorced
Married
Other/Unknown
Single
Widowed
Black or African American
Hispanic/Latino
Other
Patient refused/not reported
White or Caucasian, not Hispanic
English
Other/Unknown
Yes
No
Unknown
Other
Private
Public
Self-pay

Mean ± Std dev. or
N (%)
71.47 ± 14.244
Min – Max 18 - 106
10019 (41.3)
14239 (58.7)
2962 (12.2)
12483 (51.5)
289 (1.2)
3386 (14.0)
5138 (21.2)
1573 (6.5)
546 (2.3)
400 (1.6)
379 (1.6)
21360 (88.1)
23925 (98.6)
333 (1.4)
1982 (8.2)
5256 (21.7)
17020 (70.2)
7 (0.001)
3977 (16.4)
19703 (81.2)
571 (2.4)

A Cox proportional hazards model (Research question 4a) compared the interval from
diagnosis to referral for the variables that were significant in the ANOVA and Chi square
analyses above. The overall model showed significance; at least one independent variable was
predictive of referral (Table 3). Age showed a B coefficient of -0.62 and Exp(B) of 0.940,
meaning each year a person ages, there is 6% less likelihood of them being referred for treatment
(95%CI [0.934, 0.946]). The model revealed men were over 200% as likely as women to be
referred (B coefficient = 0.772; HR 2.165 [95% CI 1.746, 2.686]). Unmarried patients were less
than half as likely to be referred (B coefficient = -0.451; HR 0.637 [0.523, 0.776]) and the
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Table 2. Patients referred to an advanced heart failure specialist compared to patients not referred
Variable

Category

Age
Sex
Marital Status
Race/ethnicity

Preferred
Language
Current smoker
Insurance

Female
Male
Married/Significant other
Divorced/Legally
Separated/Single/Widowed
Black or African American
Hispanic/Latino
Other
White or Caucasian, not
Hispanic
English
Spanish
Other/Unknown
Yes
No
Private
Public
Self-pay

Referred
Mean ± Std.
Dev.
or N (%)
57.84 ±
12.448
155 (1.5)
462 (3.2)
367 (2.9)
236 (2.1)

Not referred
Mean ± Std.
Dev.
or N (%)
71.83 ±
14.113
9864 (98.5)
13777 (96.8)
12116 (97.1)
97.9 (23366)

67 (4.3)
13 (2.4)
19 (4.8)
496 (2.3)

1506 (95.7)
533 (97.6)
381 (95.3)
20864 (97.7)

< 0.001

608 (2.5)

23317 (97.5)

0.828

4 (2.2)
5 (3.2)
56 (2.8)
197 (3.7)
164 (4.1)
437 (2.2)
16 (2.8)

175 (97.8)
149 (96.8)
1926 (97.2)
5059 (96.3)
3813 (95.9)
19266 (97.8)
555 (97.2)

p value
< 0.001
< 0.001
< 0.001

0.057
< 0.001

publicly insured were nearly 30% more likely to be referred than the privately insured (B
coefficient = 0.261; HR 1.298 [95% CI 1.038, 1.623]).
In the sensitivity analysis including all independent variables, the overall model was once
again significant. In this model, younger age (B coefficient = -0.68; HR 0.934 [95% CI 0.925,
0.943]), male sex (B coefficient = 0.796; HR 2.216 [95% CI 1.544, 3.181]), and married status
([Reference variable Unmarried] B coefficient = -.408; HR 0.665 [95%CI 0.488, 0.905]) were
contributing to referral. This model additionally revealed that current smokers were half as likely
(B coefficient = -0.599; HR 0.549 [95% CI 0.389, 0.776]) to be referred (Table 3).
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Table 3. Time from diagnoses to referral assessed by Cox proportional hazards model
Variable Name

95% CI
95% CI
Lower
Upper
Cox regression including variables significant in ANOVA and Chi square analyses
Overall Omnibus
Tests of Model
Coefficients
Age
Sex (Male)
Marital Status
(Unmarried)
Race (White)
Race (Black/African
American)
Race
(Hispanic/Latino)
Race (Other)
Insurance Status
(Private)
Insurance Status
(Public)
Insurance Status (SelfPay)

B

SE

P value

Exp (B)

Chi square score
559.651

<.001

-.062
.772
-.451

.003
.110
.100

<.001
<.001
<.001

.940
2.165
.637

.934
1.746
.523

.946
2.686
.776

.045

.149

.360
.763

1.046

.781

1.401

-.556

.322

.084

.574

.305

1.078

.043

.266

.870
.073

1.044

.620

1.760

.261

.114

.022

1.298

1.038

1.623

.179

.283

.528

1.196

.686

2.084

Cox regression sensitivity analysis including all independent variables
Overall Omnibus
Tests of Model
Coefficients
Age
Sex (Male)
Marital Status
(Unmarried)
Race (White)
Race (Black/African
American)
Race
(Hispanic/Latino)
Race (Other)
Preferred Language
(English)
Smoking Status
(Current)
Insurance Status
(Private)
Insurance Status
(Public)
Insurance Status (SelfPay)

Chi square score
222.488

<.001

-.068
.796
-.408

.005
.184
.158

<.001
<.001
.010

.934
2.216
.665

.925
1.544
.488

.943
3.181
.905

.048

.240

.386
.841

1.049

.655

1.681

-.930

.720

.196

.395

.096

1.618

.386
.467

.359
1.037

.282
.653

1.471
1.594

.728
.209

2.970
12.174

-.599

.176

<.001

.549

.389

.776

.081
.312

.191

.103

1.366

.939

1.985

-.852

.727

.241

.427

.103

1.774
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Clinic Visit with Advanced Heart Failure Specialist
As assessed in Research Question 2, 409 of the referred patients had a clinic visit with an
advanced heart failure specialist. A Chi Square test demonstrated that 70.3% of married patients
had a clinic visit with an advanced heart failure specialist while 61.4% of unmarried patients had
a clinic visit (p=0.024, Table 4). Smoking was also associated with having a clinic visit, with a
higher proportion of non-smokers being seen by a specialist (70.0%) compared to the proportion
of smokers (55.4%, p=0.39). Age, sex, race/ethnicity preferred language, and insurance status
were not associated with having a clinic visit (Table 4).

Table 4. Patients with a clinic visit compared to patients without a clinic visit
Variable

Clinic visit
Mean ± Std.
Dev.
or N (%)

Category

Age
Sex
Marital Status
Race/ethnicity

Preferred
Language

Female
Male
Married
Divorced/Legally
Separated/Single/Widowed
Black or African American
Hispanic/Latino
Other
White or Caucasian, not
Hispanic
English

Other/Unknown
Current smoker Yes
No
Insurance
Private
Public
Self-pay
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57.49 ±
12.591
104 (67.1)
305 (66.0)
258 (70.3)
145 (61.4)

No clinic
visit
Mean ± Std.
Dev.
or N (%)
58.52 ±
12.163
51 (32.9)
157 (34.0)
109 (29.7)
91 (38.6)

44 (65.7)
10 (76.9)
8 (42.1)
340 (68.5)

23 (34.3)
3 (23.1)
11 (57.9)
156 (31.5)

0.091

403 (66.3)

205 (33.7)

0.981

6 (66.7)
31 (55.4)
138 (70.0)
107 (65.2)
294 (67.3)
8 (50.0)

3 (33.3)
25 (44.6)
59 (30.0)
57 (34.8)
143 (32.7)
8 (50.0)

p value

0.332
0.806
0.024

0.039
0.338

A Cox proportional hazards model (Research Question 4a) assessed time from diagnosis
to clinic visit for the variables which were significant in the above Chi Square analysis assessing
patients receiving a clinic visit versus those who did not. Marital status (B coefficient -0.179; HR
0.836 [95% CI 0.597, 1.172]) and smoking status (B coefficient = -0.272; HR 0.762 [95% CI
0.506, 1.146]) showed no association with clinic visit (Table 5). When all independent variables
were included in the sensitivity analysis, the overall model did not show significance (Table 5).
However, younger age was shown to contribute to patients receiving a clinic visit (B coefficient
= -0.20; HR 0.981 [95% CI 0.966, 0.995]). The hazard ratio of 0.981 predicts that with each year
of age, there is a 2% less chance of having a clinic visit.

Advanced Heart Failure Therapies
For Research Question 3, patients that had a clinic visit were evaluated for whether or not
they received advanced heart failure therapies such as heart transplantation of LVAD. When the
treatment category was combined with both heart transplant and LVAD recipients (n = 111), the
ANOVA and Chi square analyses showed no difference in any of the independent variables
between who received a treatment and who did not receive a treatment (not shown). The Cox
proportional hazards model assessing time from diagnosis to either treatment included all
independent variables as none were significant in the ANOVA and Chi square analysis above.
The overall model showed significance and at least one independent variable was predictive of
treatment. Age and Hispanic/Latino ethnicity both contributed to patients receiving a heart
failure treatment, with each year of age decreasing likelihood of treatment by 4% (B coefficient
= -0.041; HR 0.960 [95% CI 0.929, 0.991]) and Hispanic/Latino patients were more likely to
receive treatment that White patients (B coefficient = 2.161; HR 8.682 [1.475, 51.09]) (Table 6).
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Table 5. Time from diagnosis to clinic visit assessed by Cox proportional hazards model
Variable Name

95% CI
95% CI
Lower
Upper
Cox regression including variables significant in ANOVA and Chi square analyses
Overall Omnibus
Tests of Model
Coefficients
Marital Status
(Unmarried)
Smoking Status
(Current)

B

SE

P value

Exp (B)

Chi square score
2.674

.263

-.179

.172

.298

.836

.597

1.172

-.272

.208

.192

.762

.506

1.146

Cox regression sensitivity analysis including all independent variables
Overall Omnibus
Tests of Model
Coefficients
Age
Sex (Male)
Marital Status
(Unmarried)
Race (White)
Race (Black/African
American)
Race
(Hispanic/Latino)
Race (Other)
Preferred Language
(English)
Smoking Status
(Current)
Insurance Status
(Private)
Insurance Status
(Public)
Insurance Status (SelfPay)

Chi square score
16.559

.085

-.020
.256
-.185

.008
.220
.189

.010
.244
.328

.981
1.292
.831

.966
.839
.573

.995
1.988
1.204

-.455

.283

.173
.108

.634

.364

1.105

.944

.788

.231

2.571

.548

12.057

-.421
.684

.486
1.134

.386
.546

.656
1.982

.253
.215

1.701
18.305

-.268

.213

.208

.765

.504

1.161

.259
.165

.230

.474

1.179

.751

1.851

.997

.615

.105

2.710

.811

9.051

When assessing heart transplant alone (n = 57), ANOVA demonstrated age was
significantly associated with receiving a heart transplant, with a mean age of those receiving a
heart of 53.06 and those not receiving an organ of 58.31 (p=0.002, Table 7). A higher proportion
of females (23.1%) than males (13.1%) received heart transplants (p=0.016). Privately insured
patients were more likely to receive a heart transplant, with a proportion of 23.4% receiving a
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Table 6. Time from diagnosis to AHF treatment assessed by Cox proportional hazards model
Variable Name

B

SE

P value

Exp (B)

95% CI
Lower
Cox regression sensitivity analysis including all independent variables
Overall Omnibus
Chi square score
Tests of Model
19.581
0.033
Coefficients
Age
-.041
.016
.012
.960
.929
Sex (Male)
.538
.523
.303
1.712
.615
Marital Status
-.004
.355
.990
.996
.497
(Unmarried)
Race (White)
.109
Race (Black/African
-.308
.759
.685
.735
.166
American)
Race
2.161
.904
.017
8.682
1.475
(Hispanic/Latino)
Race (Other)
-.075
.999
.941
.928
.131
Preferred Language
2.038
1.339
.128
7.675
.556
(English)
Smoking Status
-.306
.427
.474
.737
.319
(Current)
Insurance Status
.425
(Private)
Insurance Status
-.571
.437
.191
.565
.240
(Public)
Insurance Status
520.808
.982
.000
.000
(Self-Pay)
11.987

95% CI
Upper

.991
4.771
1.996
3.255
51.090
6.572
105.939
1.700

1.329
.

heart, while 13.3% of the publicly insured and no self-pay heart recipients (p=0.023).
Time from diagnosis to transplant alone was also assessed, and the Cox proportional
hazards model was significant with at least one predictor of referral (Table 8). Age (B coefficient
= -0.21; HR 0.980 [95% CI 0.961, 0.998]), White race (p=0.042), Hispanic/Latino ethnicity (B
coefficient = 1.504; HR 4.501 [95% CI 1.574, 12.875]), and both public (B coefficient = -0.758;
HR 0.468 [95% CI 0.270, 0.813]) and private insurance (p=0.027) were significantly influencing
the outcome heart transplantation. For the heart transplantation sensitivity analysis assessing all
independent variables in the Cox proportional hazards model, the model was once again
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Table 7. Patients who received heart transplantation compared to patients without transplantation
Variable

Heart
transplant
Mean ± Std.
Dev.
or N (%)
53.06 ±
13.140
24 (23.1)
40 (13.1)
43 (16.7)
20 (13.8)

No heart
transplant
Mean ± Std.
Dev.
or N (%)
58.31 ±
12.33
80 (76.9)
265 (86.9)
215 (83.3)
125 (86.2)

5 (11.4)
4 (40.0)
3 (37.5)
52 (15.3)

39 (88.6)
6 (60.0)
5 (62.5)
288 (84.7)

0.048

66 (16.3)

340 (83.7)

0.978

Other/Unknown
Yes

1 (16.7)
2 (6.5)

5 (83.3)
29 (93.5)

0.229

No
Private
Public
Self-pay

20 (14.5)
25 (23.4)
39 (13.3)
0 (0)

118 (85.5)
82 (76.6)
255 (86.7)
8 (100)

Category

Age
Sex
Marital Status
Race/ethnicity

Preferred
Language
Current
cigarette
smoker
Insurance

Female
Male
Married
Divorced/Legally
Separated/Single/Widowed
Black or African American
Hispanic/Latino
Other
White or Caucasian, not
Hispanic
English

p value

0.002
0.016
0.446

0.023

significant but only age (B coefficient = -0.058; HR 0.943 [95% CI 0.902, 0.987]), White race
(p=0.011), and Hispanic/Latino ethnicity (B coefficient = 2.459; HR 11.698 [95% CI 2.191,
62.471]) were significant predictors in the model (Table 8).
When the same factors were assessed for influencing treatment with an LVAD (n=64), no
variables were shown to be significantly associated with receiving or not receiving an LVAD in
the ANOVA or Chi Square analyses (Table 9). In the Cox proportional hazards model assessing
the outcome time to LVAD, the overall model was not significant but White race (p=0.023),
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Table 8. Time from diagnoses to heart transplantation assessed by Cox proportional hazards
model
Variable Name

95% CI
95% CI
Lower
Upper
Cox regression including variables significant in ANOVA and Chi square analyses
Overall Omnibus
Tests of Model
Coefficients
Age
Sex (Male)
Race (White)
Race (Black/African
American)
Race
(Hispanic/Latino)
Race (Other)
Insurance Status
(Private)
Insurance Status
(Public)
Insurance Status (SelfPay)

B

SE

Chi square score
42.970
-.021
-.384

.010
.274

.069

P value

Exp (B)

<0.001
.980
.681

.961
.398

.998
1.164

.484

.034
.160
.042
.886

1.072

.415

2.769

1.504

.536

.005

4.501

1.574

12.875

.528

.647

.415
.027

1.695

.476

6.030

-.758

.282

.007

.468

.270

.813

-11.042

250.646

.965

.000

.000

3.586E+208

Cox regression sensitivity analysis including all independent variables
Overall Omnibus
Tests of Model
Coefficients
Age
Sex (Male)
Marital Status
(Unmarried)
Race (White)
Race (Black/African
American)
Race
(Hispanic/Latino)
Race (Other)
Preferred Language
(English)
Smoking Status
(Current)
Insurance Status
(Private)
Insurance Status
(Public)
Insurance Status (SelfPay)

Chi square score
28.476

.002

-.058
-.233
-.551

.023
.576
.543

.011
.686
.310

.943
.792
.576

.902
.256
.199

.987
2.451
1.671

-.619

1.087

.022
.569

.539

.064

4.533

2.459

.855

.004

11.698

2.191

62.471

-1.184
.211

1.313
1.219

.367
.863

.306
1.235

.023
.113

4.015
13.477

-1.474

.816

.071

.229

.046

1.134

.831
-.333

.547

.543

.717

.245

2.096

-11.666

552.491

.983

.000

.000

.
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Table 9. Patients who received a LVAD compared to patients who did not receive LVAD
Variable

Category

Age
Sex
Marital Status
Race/ethnicity

Preferred
Language

Female
Male
Married
Divorced/Legally
Separated/Single/Widowed
Black or African American
Hispanic/Latino
Other
White or Caucasian, not
Hispanic
English

Other/Unknown
Current smoker Yes
No
Insurance
Private
Public
Self-pay

LVAD
Mean ± Std.
Dev.
or N (%)
58.12 ±
12.591
9 (8.7)
48 (15.7)
37 (14.3)
19 (13.1)

No LVAD
Mean ± Std.
Dev.
or N (%)
57.39 ±
12.777
95 (91.3)
257 (84.3)
221 (85.7)
126 (86.9)

2 (4.5)
9 (90.0)
2 (25.0)
50 (14.7)

42 (95.5)
1 (10.0)
6 (75.0)
290 (85.3)

0.222

57 (14.1)

346 (85.9)

0.321

0 (0)
6 (19.4)
18 (13.0)
14 (13.1)
42 (14.3)
1 (1.3)

6 (100)
25 (80.6)
120 (87.0)
93 (86.9)
252 (85.7)
7 (8.7)

p value
0.683
0.072
0.730

0.363
0.947

LVAD, left ventricular assist device

Hispanic/Latino ethnicity (B coefficient = 3.521; HR 33.833 [95% CI 3.207, 356.968]), and
public insurance (B Coefficient = -1.396; HR 0.248 [95% CI 0.077, 0.792]) affected the
likelihood of receiving a LVAD (Table 10).

Mortality
In Research Question 4b, Logistic regression analysis was performed to assess 1-year
mortality from the date of diagnosis. In the initial regression model using only variables
significant in the above ANOVA and Chi square analyses, increasing age and Hispanic/Latino
ethnicity were associated with death within 1 year of heart failure diagnosis (Table 11). A second
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Table 10. Time from diagnosis to LVAD implantation assessed by Cox proportional hazards
model
Variable Name

B

SE

P value

Exp (B)

95% CI
Lower
Cox regression sensitivity analysis including all independent variables
Overall Omnibus
Chi square score
Tests of Model
14.641
.146
Coefficients
Age
-.029
.023
.213
.972
.929
Sex (Male)
2.473
1.438
.085
11.862
.709
Marital Status
.520
.490
.289
1.681
.644
(Unmarried)
Race (White)
.023
Race
-.069
1.071
.949
.934
.115
(Black/African
American)
Race
3.521
1.202
.003
33.833
3.207
(Hispanic/Latino)
Race (Other)
1.441
1.430
.313
4.227
.257
Preferred Language 16.662 488.662
.973
17221536.689
.000
(English)
Smoking Status
.524
.540
.332
1.689
.586
(Current)
Insurance Status
.063
(Private)
Insurance Status
-1.396
.593
.019
.248
.077
(Public)
Insurance Status
3166.835
.996
.000
.000
(Self-Pay)
14.828

95% CI
Upper

1.017
198.496
4.392
7.613
356.968
69.646
.
4.864

.792
.

LVAD, left ventricular assist device

logistic regression model including all independent variables from this study revealed that
current smoking was an additional predictor of 1-year mortality (Table 11). Death within hospital
stay for transplant and LVAD recipients, as well as mortality within one year of receiving each
treatment were also assessed, and no independent variables showed significance in any of those
models (not shown).
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Table 11. Factors affecting 1-year mortality from date of diagnosis assessed by logistic
regression
Variable Name
Estimate
SE
Z value
P value
Logistic regression including variables significant in ANOVA and Chi square analyses
(Intercept)
-14.1
138.0
-.102
0.919
Age
0.053
0.003
18.75
<0.001
Sex (Male)
0.019
0.066
0.294
0.768
Marital Status
0.118
0.062
1.890
0.058
(Unmarried)
Race (White)
-0.443
0.296
-1.499
0.134
Race (Black/African
-0.576
0.323
-1.786
0.074
American)
Race
-1.034
0.407
-2.540
0.011
(Hispanic/Latino)
Race (Other)
-0.494
0.387
-1.276
0.202
Insurance Status
9.50
0.069
138.0
0.945
(Private)
Insurance Status
9.27
138.0
0.067
0.946
(Public)
Insurance Status
10.25
138.0
0.074
0.941
(Self-Pay)
Logistic regression sensitivity analysis including all independent variables
(Intercept)
-14.36
136.6
-0.105
0.916
Age
0.055
0.003
19.03
<0.001
Sex (Male)
0.019
0.066
0.284
0.776
Marital Status
0.095
0.063
1.520
0.128
(Unmarried)
Race (White)
-0.438
0.296
-1.480
0.139
Race (Black/African
-0.580
0.323
-1.795
0.072
American)
Race
-0.921
0.417
-2.203
0.028
(Hispanic/Latino)
Race (Other)
-0.421
0.394
-1.071
0.284
Preferred Language
-0.389
0.384
-1.014
0.310
(English)
Smoking Status
0.254
0.071
3.591
<0.001
(Current)
Insurance Status
9.53
136.6
0.070
0.944
(Private)
Insurance Status
9.31
136.6
0.068
0.946
(Public)
Insurance Status
10.27
136.6
0.075
0.940
(Self-Pay)
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CHAPTER V
DISCUSSION
Patients diagnosed with heart failure face similar barriers as the patients who go through
the extensive evaluation process for AHF therapies. This research investigated potential
demographic, social, and economic factors that affect referral to an AHF specialist, whether
patients have a clinic visit, and whether they ultimately receive treatment. The results of this
investigation as described below emphasize the obstacles patients face with regards to continuity
of care and access to healthcare services.

Referrals for AHF Services
Patients with a heart failure diagnosis were more likely to be referred to a heart failure
specialist is they were younger, male, or married (Table 2). While there may be age constraints
on the eligibility for a heart transplant, the age restrictions have become less strict over the year
with more patients over the age of 70 being transplanted. 139,140 The leadership council of the
professional society, American College of Cardiology, has noted that lack of clear guidance for
cardiologists and internal medicine physicians on which patients to refer for AHF services has
led to delays in referral, often to the point candidacy is no for heart transplantation or LVAD is
longer possible.66 Age in itself is not a contraindication for either treatment, however increasing
age is a predictor of mortality post-heart transplantation. 140 In LVAD recipients over the age of
70, similar 2-year survival and quality of life to younger recipients have been shown. 141
Furthermore, other medical, pharmacological, and palliative options should be assessed by an
AHF specialist. Previous research has also demonstrated lack of referral for cardiac services for
older patients, although the authors note than it is unknown how many patients of advanced age
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decline invasive testing and procedures.39 Knowing a person’s age alone cannot determine
whether or not a patient may benefit from advanced heart failure services and researchers have
voiced opinions that even if a patient may be presumed to not benefit from a heart transplant or
LVAD, they still deserve a minimum of one expert assessment by a heart failure specialist. 10
This reinforces the ethical claim that equity is needed in referral for AHF services and that
younger patients are not selected for in the referral process.
Men were twice as likely to be referred compared to women as shown in both the Chi
Square (Table 2) and Cox proportional hazards model (Table 3). The difference in clinical
presentation of heart failure in men and women104 might be thought to contribute to this
disparity, however, the percentage of men (58.7%) diagnosed with heart failure was not twice
that of women (41.3%) in the overall cohort (Table 1). A well-cited study from 1999 found that
even after adjustment for symptoms, clinical characteristics, and disease assigned by the
physician, men were more likely to be referred for cardiac catheterization than women. 142 The
authors of that study concluded that implicit physician bias was involved in recommendations for
chest pain, which in turn affects differences in treatment of cardiovascular disease by sex.
Similar factors could be at play in the current study, although the current research did not assess
decision-making at the physician level and therefore cannot draw similar conclusions as done in
the previous study. Bias could be introduced at one of many steps in the referral process,
including recognition of initial symptoms by the provider, when making recommendations, the
degree of communication, and the referrer’s perception about the patient’s suitability for
advanced interventions.11 to name a few, and each step warrants future investigation. Unbiased
decision-making is an expectation of the American healthcare system and discrimination based
on sex or gender violates the just allocation of healthcare services.
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According to the Chi square analysis, more referrals occurred for patients in the Black
and Other racial/ethnic groups (Table 2), but race did not show significance in either Cox
proportional hazards model (Table 3). More referrals in the Black and Other racial/ethnicity
categories is an interesting finding because much of literature on various conditions reports
inadequate referral and treatment for non-White patients 29–32,142 A possible theory explaining
these findings is the conscious dedication of clinicians to improve their implicit bias. There are
many calls in the literature explaining the need for training requirements to help reduce clinician
implicit bias.143 One of the main solutions, however, is to diversify the provider pool which
should be considered a national priority.144
Patients with public insurance at the time of diagnosis had more referrals, as shown in the
Chi Square analysis (Table 2) and was confirmed by the Cox proportional hazards analysis
(Table 3). Since inclusion in this study required a diagnosis of heart failure, the patients that
never received such a diagnosis were not captured. There are many reasons why a patient who
has heart failure may never see a clinician to receive a diagnosis, with lack of appropriate
insurance coverage being one main reason. The uninsured have a more difficult time getting the
medical care they need, with uninsured persons being less likely to see a clinician after an
unintentional injury or presence of a new chronic condition. 145 Health insurance has been shown
to not only improve mortality, but also improve self-rated health and reduce likelihood of
depression, acting as a gateway to medical care.146 Improving chronic conditions such as
hypertension, diabetes, and metabolic syndrome, which are risk factors for heart failure, is
important in reducing disparities in access to AHF services. 14 With over 28 million (8.6%) of
Americans recorded as uninsured in the recent Census data, 46 the preventable health challenges a
large portion of our population faces is a major national crisis.

61

Clinic Visit with AHF Specialist
Once patients had a referral, they were more likely to have a visit with an AHF specialist
if they were married. Previous research has found that married patients had more outpatient
visits147 and other research has demonstrated that increased continuity of care reduces
hospitalizations.148 Patients that are married or have a significant other may have the benefit of
“marriage protection,” which is the idea that married people are healthier, especially men,
because of the physical and emotional support a spouse provides. 147,149 Single and divorced
persons, especially men, have been shown to have negative effects on health, 150 and the
“bereavement effect” similarly affects widowed patients. 149,151 While increased clinic visits by
married patients may have to do with increased medical adherence in this group, AHF programs
should be mindful of processes that could be implemented to improve likelihood of follow
through in single patients once a referral is made, which would improve equity of services based
on marital status.
Patients that had a clinic visit were also more likely to be nonsmokers, despite no
association above between smoking status and referral. Patients that smoke have been shown to
have more outpatient visits than non-smokers,152 but the distinction between primary care visits
and specialist visits has not been made. Our study suggests that while a patient that smokes may
be seen in an initial visit in which their heart failure was diagnosed, they may not follow through
with an appointment with a specialist. Previous research has demonstrated that current smokers
are more likely to have incomes below the national poverty level and less likely to have health
insurance than former smokers and non-smokers,152 which would have a direct effect on
healthcare utilization. With a number of intersectional characteristics at play, efforts to improve
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equity in access to healthcare services is essential to reduce the disparities in follow through with
outpatient care.

AHF Treatment
The analysis demonstrated that more stringent criteria are used for heart transplantation
eligibility compared to LVAD. When both treatments were combined, the ANOVA and Chi
square analyses showed no association with any of the independent variables on whether or not
patients received treatment. However, the Cox proportional hazards sensitivity analyses revealed
that younger age, White race, and Hispanic ethnicity were associated with treatment. Further
analysis revealed that younger age was also associated with whether patents received a heart
transplant (Table 8), but not with whether patients received a LVAD (Table 10). As mentioned
above, the general guidance is that heart transplant candidates be 70 years of age or less, 120
although guidelines for LVAD management do not mention an upper cutoff for age. 153 The most
advanced age receiving a transplant was 70 in the current analysis, and 75 was the highest age
for LVAD recipients. Adamson et al. has reported ages of LVAD recipients up to 87 years. 141
White race and Hispanic ethnicity were associated with receiving any AHF treatment as
shown in the Cox proportional hazards models. Further, while no other independent variables
showed an effect on receiving an LVAD, the sensitivity analysis once again revealed that White
and Hispanic/Latino patients were more likely to receive an LVAD compared to the Black and
Other racial category patients (Table 10). Previous research has established that White patients
have greater access to healthcare services than other racial and ethnic groups. 50,142 While
Hispanic patients have been noted in the literature to have more cardiovascular risk factors and
decreased access to healthcare,154 the current research showing disparities in treatment suggests

63

Hispanic patients may be more likely than Black patients or those in Other racial categories to
follow through with recommended procedures. This finding may intersect with increased levels
of familism and allocentrism in the Hispanic community, which in itself has the potential for
positive health implications.155 In an unpublished study, the authors demonstrated that social
support is associated with selection for AHF therapies.12 Though Hispanic patients were not
shown in the current study to have more referrals or more AHF clinic visits than other racial
groups, their increased likelihood of treatment may be related to their social support structure.
Conversely, the results could be interpreted to illustrate lack of treatment recommendations for
patients in the Black and Other racial categories. Reduced access to healthcare services has been
repeatedly noted in the literature with regards to Black patients. 57,142,156
Additionally, there are many points in the disease trajectory that patients may make
decisions that affect their treatment, either intentionally decision-making or unknowingly. For
example, patients with cardiac symptoms may not recognize their symptoms 56 and either avoid
or delay care. There may be cultural or spiritual reasons a patient may not choose to see a
provider or follow through with planned procedures. 28 Or if a patient does see a provider,
patients may not trust or accept the assessment or recommendations they are given by a
physician.11 Any perceptions of discrimination would impact a patient’s decision-making and
trust in the medical system, ultimately affecting continuity of care.
It must be noted that race is a social construct and not a biological construct. Members of
any racial or ethnic categorization have a wide range of varying socioeconomic and structural
barriers present. Even epidemiologists question racial/ethnic categorization of individuals and
the utility of the categories relating to public health endeavors. 43 Further, the link between race
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and systemic and structural racism is undeniable,157 leading to unequal clinical treatment as
explored in this study.
The Chi square showed a higher proportion of females received heart transplants in this
study compared to males, even though the number of females transplanted was lower than that of
males (Table 7). This finding was not significant in the subsequent Cox proportional hazards
models and is inconsistent with what is reported in the literature, as more males receive heart
transplants than females on the national level.2,140
The privately insured were also more likely to receive a heart transplant according to the
Chi Square results, and both private and public insurance showed significance in the Cox
proportional hazards model that included age, sex, race, and insurance status with private
insurance having a positive effect on transplantation and public insurance having a negative
effect; however, insurance status did not show significance in the sensitivity analysis (Table 8).
The insurance requirement for transplantation has been well-documented in the literature 7,8,26 and
support the current findings. The sensitivity analysis, however, implies that other variables in the
model, such as age and race, had more of an effect on receiving a transplant than type of
insurance.

Mortality
One-year mortality after heart failure diagnosis was associated with increased age and
Hispanic/Latino ethnicity (Table 11), but neither variable was significant in the logistic
regressions assessing 1-year survival post-transplant and post-LVAD. Therefore, the older
patients that were dying within one year of diagnosis were those that did not receive AHF
therapies. Older patients are more likely to have other comorbidities which would affect
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mortality. However, this study suggests patients that lack of referral and eligibility for advanced
heart failure services affects patient mortality in the advanced age group.
The higher mortality rates of Hispanic/Latino patients in the whole cohort but not in the
treatment groups likewise suggests that lack of referral and visit with an AHF specialist
contributes mortality. It is also possible that patients may turn down services once eligible, due
to cultural or spiritual beliefs that impact decision-making. 28
The sensitivity analysis also revealed that smoking was associated with 1-year mortality
post-heart failure diagnosis. Smoking is a leading cause of preventable disease, with over
480,000 deaths attributable to smoking per year, and contributes to cardiovascular disease
through various mechanisms.158 It was surprising that smoking did not show as a significant
predictor for AHF treatment, and even more surprising was the two patients recorded as current
smokers who received heart transplants. This was likely an artifact of using baseline data; even
though the patients were smokers at the time of diagnosis, they likely stopped by the time they
were selected for transplant candidacy.

Limitations and Future Research
The current study investigated the demographic, social, and economic variables available
through the electronic data pulls at one hospital system. While additional variables would make
the study more robust, they were not available for most patients. Therefore, this research
provides a limited view of the factors influencing the referral and care trajectory in heart failure
patients. Further, this research does not take into account medical factors that may contribute to
differences in referral and treatment. For example, some providers may not refer patients to
specialists due to presence of certain comorbidities. The factors affecting referral outside of the
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independent variables examined in this study were not evaluated. Future research should include
looking at the medical reasons that contribute to lack of referral. Also, this research does not take
into account changes in insurance coverage over the course of the patient’s heart failure disease
trajectory, or for changes in any of the other independent variables. All non-English languages
were categorized together due to limitations with sample size. Preferred language did not
influence referral, clinic visit, treatment, or mortality in any of the analyses above, which may be
an artifact of this grouping.
Future research on referrals data should also include multicenter data from various
geographic locations. Guidelines for referral and treatment vary across AHF programs, so
differences between institutions would be interesting to understand.
Epidemiological research inherently makes claims about social differences, such as race,
gender, and class. The literature review attempts to delve into some of these wrongful claims but
is not comprehensive in doing so. Additionally, the current research did not examine the
difference between race and gender, due to the insufficient availability of information beyond
“male” and “female” in the dataset. When data is available, accounting for gender is important in
understanding additional barriers affecting access to AHF services. Researchers should be
mindful of their use of labels as they can exacerbate social inequalities. 43
Notably, this research does not take into account the many structural barriers in place
affecting referral, both before and after a heart failure diagnosis is made. Access to a provider to
make the initial heart failure diagnosis often requires insurance coverage as well as the work
flexibility, feasibility with geographic proximity, assistance with any caregiving responsibilities,
and transportation to visit a provider. Without insurance or a means to pay for healthcare,
patients may avoid having doctors’ visits and therefore are never captured in medical datasets.
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This is in part due to employment-based insurance coverage in the United States, which
contributes to the disparities in health between patients with more or less means as patients may
choose not to pay for health insurance or healthcare entirely due to the prohibitive costs. These
structural barriers are outside the scope of this investigation.

Interdisciplinary Research
AHF services require interdisciplinary collaboration between clinical and non-clinical
professionals from varying fields. The trajectory from heart failure diagnosis to treatment is
complex and unique for each patient. Patients diagnosed with heart failure may meet with
professionals in upwards of 10 different disciplines. Therefore, the findings of this investigation
are of interest to a multidisciplinary audience and have implications for changes at the level of
transplant programs, hospital systems, state government, and federal government entities.
This research synthesized the clinical, ethical, and political aspects of AHF treatment as
well as access to healthcare services as whole. The allocation of donor organs is a complex
process, rich with moral underpinnings and medical requirements. Therefore, any investigation
involving transplant practices requires an ethical perspective. The allocation system is based on
policies which are influenced both by clinical outcomes and justice in distribution. The same
approach should be considered for all healthcare services, as justice is needed to increase equity
in care at the primary care and outpatient level.
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Recommendations
Clinical and Health System Recommendations
Tools and guidance are needed in order for primary care physicians and cardiologists to
appropriately refer patients to an AHF specialist. An electronic algorithm within the EMR to
alert physicians in a timely manner when certain criteria are met has been developed, 159 however,
the exact criteria needs further development. In the system reported by Evans et al, a patient aged
80 years old or older would not elicit a prompt in the system for AHF referral. 159 Additional
research is needed to identify evidence-based guidelines for referral. Timely referral is an
important consideration when developing future guidelines.
Cultural training to improve implicit bias in clinicians is an important component of
improving equity in access to AHF services. Including such training as part of the medical school
curriculum and as continuing education for practicing clinicians is essential to improve access
and health outcomes. Many publications have recommended cultural competency training to
improve patient-provider relations.11,25,27,28,37,154,160
Health systems should be aware of systems in place that may incentivize clinicians to
promote disparities in access.25 Clinician should be rewarded for their invaluable effort and
expertise but doing so at the detriment of vulnerable populations must be avoided and practices
that reduce barriers should be rewarded. Further, diversifying the workforce of health
professionals will have vast benefits on healthcare equity.

Policy Recommendations
Insurance coverage through Medicaid should be available to all patients in need of organ
transplantation in the United States. Medicare currently requires a 20% copay for heart
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transplantation.161 Universal insurance coverage would certainly improve equity in
transplantation, and it is interesting to consider the effects on organ donation that might occur if
the government provided this service to the nation. State and federal representatives should be
assessing areas of inequity in healthcare delivery and looking for available funds to help with
solutions. This should also include healthcare coverage that encourages outpatient visits and
continuity of care, which would improve access to care as well as health outcomes.
As mentioned above, CMS requires transplant programs to report institutional outcomes
through UNOS in order to monitor performance and maintain CMS coverage. This practice may
encourage programs to select low-risk patients. A recommendation would be for CMS and
UNOS performance algorithms to account for equity in transplantation, thus encouraging
transplant centers to identify patients from a more diverse set of criteria. Wadhwani et al.
suggests that transplant centers should be financially incentivized to choose candidates with
limited financial resources, and this should continue through the life of the transplant. 132
Addressing income inequality is another area that should be of national priority. As the
richest and poorest members of our society become farther and farther apart, so will increase the
disparities in both access to healthcare and the health of our nation. From a productivity level,
the health of our citizens is of upmost importance, which is important in the context of the ethical
principle, utility. The application of justice in the distribution of healthcare to improve the health
of our citizens is also advantageous since good health across all populations is essential for the
functioning of society.162 We, as a society, have a moral duty to reduce health disparities since
the principle, respect for all persons, is not met when there are such drastic inequalities in health.
Further, the presence of health disparities perpetuates the historical injustices of disenfranchised
populations.163
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Conclusions
This research was a first of its kind investigation examining a large cohort of heart failure
patients and the factors that affect referral, clinic visits, and treatments. Current registries do not
record patients that are never evaluated or eligible for AHF therapies, which was the population
of interest in the current study. The study included a total of 24,258 patients diagnosed with heart
failure at a single hospital system. Patients that were referred were more likely to be young,
male, married, Black race, and have public insurance. Patients who had a clinic visit with an
AHF specialist were more likely to be young, married, and non-smokers. Patients receiving
advanced heart failure treatments were more likely to be White race or Hispanic ethnicity, and
specifically heart transplant recipients were also younger and had private insurance. Hispanic
patients and smokers had increased risk of 1-year mortality. These findings show differences in
selection at each step in the care trajectory of heart failure patients as well as injustices in access
to healthcare services. Future research should investigate additional factors influencing referral
as well as compare multi-center data. Diversifying the healthcare workforce is an important step
in reducing the health disparities in our country.
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